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Abstract 
Thymidylate synthase (TS) is the only de novo source of thymidylate (dTMP) for DNA 
synthesis and repair. Drugs targeting TS protein are a mainstay in cancer treatment but off-
target effects and toxicity limit their use. Cytosolic thymidine kinase (TK1) and 
mitochondrial thymidine kinase (TK2) contribute to an alternative dTMP-producing 
pathway, by salvaging thymidine from the tumour milieu, and may modulate resistance to 
TS-targeting drugs. We have previously shown that TS antisense molecules 
(oligodeoxynucleotides, ODNs, and small interfering siRNA, siRNA) sensitize tumour cells, 
both in vitro and in vivo, to TS targeting drugs. As both TS and TKs contribute to cellular 
dTMP, we hypothesized that TKs mediate resistance to the capacity of TS siRNA to sensitize 
tumour cells to TS-targeting drugs. Downregulation of TKs with siRNA enhanced the 
capacity of TS siRNA to sensitize tumour cells to traditional TS protein-targeting drugs 
(5FUdR and pemetrexed). Combined downregulation of these enzymes is an attractive 
strategy to enhance TS-targeted anticancer therapy. TK2 can phosphorylate both thymidine 
and deoxycytidine to generate dTMP and dCMP, precursors for dTTP and dCTP, respectively. 
dCTP negatively regulates deoxycytidine kinase (dCK), another enzyme that phosphorylates 
deoxycytidine as well as the anticancer drug gemcitabine. Antisense knockdown of TK2 
could reduce TK2-produced dCMP, thus decreasing dCTP levels and inhibition of dCK, and 
lead to increased dCK activity, gemcitabine activation, and anticancer effectiveness. Given 
the substrate promiscuity of TK2, we hypothesized that: (1) TK2 can mediate human tumour 
cell resistance to gemcitabine, (2) antisense downregulation of TK2 can overcome that 
resistance, and (3) TK2 siRNA-induced drug sensitization results in mitochondrial damage. 
siRNA downregulation of TK2 expression sensitized MCF7 and HeLa cells to gemcitabine, but 
did not sensitize A549 cells (low TK2 expresser). Treatment with TK2 siRNA and 
gemcitabine: 1) decreased mitochondrial redox status, 2) decreased mitochondrial DNA 
(mtDNA:nDNA ratio), and 3) decreased mitochondrial activity. This is the first 
demonstration of a direct role for TK2 in gemcitabine resistance, or any independent role in 
cancer drug resistance, and further distinguishes TK2 from other dTMP-producing enzymes. 
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Chapter 1  
« Introduction » 
Each section, and similarly each sub-section, is organized in a reverse pyramid fashion to 
take the reader from a broad overview of the topic at hand into project-related 
specifics. The purpose of this section is to establish a basic understanding of RNA 
interference, cancer, and mechanisms by which deoxythymidine monophosphate (or 
thymidylate) is produced for DNA synthesis and repair. Subsequently, siRNA in the 
treatment of human disease is introduced and, specifically, its potential application to 
the treatment of cancer. In relation to this, small molecule inhibitors of thymidylate 
production used in anticancer therapy, and mechanisms of resistance to these drugs, 
are discussed, and antisense is suggested as a way to combat resistance. Finally, a short 
explanation summarizing and connecting these topics is presented in specific relation to 
the rationale for the project (the combined use of small interfering RNAs and small 
molecule drugs to improve upon the inhibition of tumour cell proliferation) prior to 
stating the hypotheses.  
1.1 Small interfering RNA (siRNA) 
1.1.1 RNA interference molecules and the RISC complex 
In eukaryotic cells, the regulatory mechanism of RNA interference (RNAi) contributes to 
the control of gene activity and expression. RNAi, a phenomenon first described in the 
nematode C. elegans, is a process by which short double-stranded RNA (dsRNA) 
molecules down-regulate a specific gene product by complementary, base-guided 
cleavage of target mRNA [1]. The determination of what constitutes target mRNA is 
based upon Watson-Crick sequence complementarity with the antisense RNA molecule  
loaded into the RNA induced silencing complex (RISC): the target mRNA is the sense 
strand. In RNAi, dsRNA molecules, approximately 19-23 nucleotides in length, are 
loaded into the RNA-induced silencing complex (RISC) and lead to post-transcriptional 
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gene silencing (PTGS) by mRNA degradation or translational inhibition of target mRNA 
transcripts [2, 3]. The optimal siRNA for use in mammalian cells has been determined, 
by extensive research, to be a 21 nucleotide duplex with 2 nucleotide 3’-overhangs at 
both ends [4].  
There are a number of different RNAi molecules that utilize RISC for control of gene 
expression, for example: (i) microRNAs (miRNAs), (ii) short-hairpin RNAs (shRNAs), and 
(iii) small-interfering RNAs (siRNAs) - which may either be synthetically made and 
introduced or produced endogenously from longer dsRNA molecules in the cell [1, 5, 6]. 
miRNAs are a form of endogenous RNAi within the cell that regulate the gene 
expression of multiple target genes through partial- to perfect complementarity 
sequence matches. shRNAs may be constitutively expressed from a promoter to 
produce miRNA-like or siRNA-like molecules that result in long-term, more continuous, 
gene silencing. In contrast, siRNAs are a form of transient RNAi that are generally 
synthesized to be perfect sequence matches to their target mRNA and, compared to 
shRNAs, have a decreased risk of toxicity related to the overloading of upstream 
components of the endogenous miRNA RISC-mediated silencing pathway [1, 2, 5-7]. 
While all 3 types of RNAi molecules listed utilize RISC for silencing, the process of 
formation and RISC association is slightly different (Figure 1).  
The RISC complex itself is composed of 4 different enzymes: Dicer, TAR-RNA binding 
protein (TRBP), protein activator of PKR (PACT), and Argonaute 2 (Ago2) [3, 8, 9]. The 
Dicer enzyme is an RNaseIII endonuclease responsible for processing of pre-miRNA and 
dsRNA molecules to the appropriate length for incorporation and use in RISC [10-12]. 
Dicer then interacts with TRBP, which contributes to sensing and loading of dsRNA 
molecules into a RISC complex with Ago2 present [13-16]. The PACT enzyme is thought 
to contribute to enhancement of pre-miRNA processing, as well as increased stability 
and activity of active RISC [14, 17]. Ago2 is the catalytic core of the RISC complex and is 
responsible for the cleavage and release of the target mRNA [9, 18-24]. In general, 
perfect or near-perfect complementary matches will result in mRNA cleavage, whereas 
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partial complementarity will result in the repression of translation (Figure 1). The 
nucleotides in positions 2-8 of the antisense strand represent the seed region of the 
molecule and the degree of complementarity between these nucleotides and the target 
mRNA is most important for determination of the mechanism of silencing (via cleavage, 
or translational repression and destabilization) and antisense on- and off-target mRNA 
silencing [3, 25-28]. 
The antisense molecule of choice for the experiments described in this thesis is siRNA. In 
particular, the transient nature of siRNA inhibition of mRNA and its decreased toxicity 
compared to shRNA were ideal for the type of therapeutic application envisioned. 
 
  
Figure 1: miRNA, shRNA and siRNA processing, RISC association and mRNA silencing.
miRNA (A), shRNA (B) and siRNA (
perfect sequence matches to mRNA will result in mRNA cleavage, while partial sequence 
matches result in physical inhibition of mRNA translation followed by degradati
bodies of the cytoplasm. This figure is an adapted version of the image found in 
been used with written authorization and consent from Elsevier Ltd.
C) processing and incorporation into RISC. Perfect or near
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1.1.2 Challenges of using siRNA (and RNAi) as therapeutics 
siRNA, and other RNAi molecules, are unstable in vivo due to an abundance of 
endonucleases that promote their degradation, and rapid renal clearance [30]. In the 
movement towards the use of siRNAs and RNAi molecules as therapeutics, several 
challenges became apparent and will be discussed in more detail below: (i) delivery of 
the molecules to the cells, (ii) specificity of the molecules for their intended mRNA 
target vs. targeting other molecules with similar sequence characteristics, (iii) stability of 
the siRNA within bodily fluids, and (iv) innate immune system activation as the 
molecules are recognized as foreign [29]. To meet these challenges, researchers have 
improved upon the chemical makeup of RNAi molecules and developed nucleic acid 
delivery vehicles. 
1.1.2.1 Chemistry of siRNA molecules 
To improve upon the pharmacokinetic and pharmacodynamic properties of siRNAs, and 
other RNAi molecules, modifications have been made to the base, sugar and/or 
backbone of the RNA molecules in an attempt to increase specificity and affinity, while 
decreasing degradation and immune stimulation [31-33]. With respect to backbone 
substitutions, phosphorothioate modification, where a sulfur atom replaces a 
phosphate oxygen atom, is widely used to decrease nuclease degradation and prevent 
renal clearance [34]. Other backbone modifications include: phosphodiester, 2’-O-
methyl, and locked nucleic acids that contain an extra bridge between the 2’ oxygen and 
4’ carbon of the ribose that locks the sugar into the 3’endo confirmation. Modifications 
to the ribose sugar include 2’-O-methyl (2’-OMe), 2’fluoro (2’-F), 2’-O-methoxyethyl (2’-
MOE) and 2’-O-methyl4-pyridine (2’-O-CH2Py(4)), and 2’-ribose modifications have been 
shown to increase stability, affinity, and potency [29, 35, 36]. 2’-O-methylation of the 
ribose, specifically of the RNA in positions 2 and 8 of the antisense strand, has been 
observed to decrease intravascular degradation and innate immune stimulation as well 
as reduce off-target mRNA silencing without affecting on-target silencing of perfectly 
complementary mRNA targets [25, 32, 36-39]. 
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1.1.2.2 Innate immune system activation  
There are a number of pattern recognition receptors that have evolved to recognize 
pathogen-associated molecular patterns and initiate an immune response based on the 
recognition of structural features of foreign molecules. When exogenous siRNAs and 
other RNAi molecules are introduced into in vitro and in vivo systems, activation of the 
innate immune system and an interferon-mediated activation response can occur as 
result of these molecules being recognized as alien, generally in a sequence-
independent manner [40]. In particular, toll-like receptors (TLRs) 3, 7, 8, and 9, 
interferon-induced protein kinase R (PKR), and retinoic acid inducible gene I (RIG-I) are 
responsible for the activation of the innate immune system in response to RNA- and 
DNA-based RNAi molecules [40-43]. TLR3 recognizes dsRNA molecules, TLR7 and TLR8 
recognize ssRNA, TLR9 recognizes hypomethylated DNA (and RNA) rich in CG 
dinucleotides, PKR recognizes dsRNA molecules of greater than 33 nucleotides, and RIG-
I recognizes uncapped, 5’-tri-phosphorylated dsRNA and dsRNA longer than 100bp [40, 
43-49].  
siRNAs and RNAi molecules have been experimentally modified to reduce immune 
stimulation. The list below represents two specific examples of these modifications:  
Firstly, it has been determined that optimized siRNA are 21-nucleotide duplexes with 2-
nucleotide 3’- overhangs that avoid known immunogenic sequences and have reduced 
capacity to activate TLRs (specifically TLR3 and TLR7), which is based primarily on length. 
For example, the sequence 5´-GUCCUUCAA-3´ is capable of specifically activating TLR7 
[4, 50, 51]. Secondly, the introduction of 2 or 3 residues into an siRNA that are 2’OMe-
modified can prevent immune activation as the 2’OMe groups acts as competitive 
inhibitors of TLR7 activation, thereby inhibiting cytokine production without affecting 
silencing ability [41, 52]. Other sequence characteristics to optimize siRNAs that do not 
pertain to avoidance of immune stimulation are discussed below.    
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1.1.2.3 Delivery vehicles 
Naked siRNAs are not stable in vivo or in vitro for long periods of time, may generate an 
immune response, and suffer from poor cellular uptake [29]. Along with increased 
susceptibility to enzymatic degradation, intrinsic physicochemical properties of siRNAs 
pose additional challenges to the successful delivery of siRNAs into cells and therapeutic 
utilization. Those properties include their small size, hydrophilicity, and net negative 
charge [53]. Mechanisms to achieve successful delivery of RNAi molecules may be 
categorized into: (1) physical delivery methods, (2) conjugation to targeting molecules, 
and (3) carrier-mediated delivery methods [54-56].  
Of particular importance to this thesis are carrier-mediated delivery methods, because 
the transfection reagent (delivery agent) used for experimentation is the cationic-
liposome Lipofectamine 2000 (LF2K or LFA2K), which falls into this delivery classification. 
First demonstrated by Felgner et al. in 1987, lipofection, or the delivery of DNA (or RNA) 
into the cell via cationic lipids that spontaneous entrap the molecules into liposomes, is 
an efficient and highly reproducible way to facilitate the entry of RNAi molecules into 
the cell. This method is associated with less toxicity than other delivery methods, such 
as viral vectors used to deliver shRNA plasmids [57, 58]. Positively charged cationic lipids 
work to attract and encompass negatively charged nucleic acid RNAi molecules, 
resulting in spontaneous formation of liposomes containing RNAi molecules within or on 
the lipid carrier. These liposomes allow the RNAi molecules to overcome the 
electrostatic repulsion of the negatively charged cell membrane (CM) and facilitate 
passage across the CM and/or endocytosis [59, 60]. Since their initial application, these 
molecules have been further refined and modified to encourage greater cellular uptake, 
decrease systemic non-specific toxicity, facilitate cell- or tissue-specific targeting, and 
increase endosomal escape [53, 59, 61, 62]. While the LF2K reagent used here has been 
shown to be more toxic than other lipofection agents (especially when transfecting DNA 
plasmids), it was also superior in its ability to specifically delivery siRNAs into cells, allow 
endosomal escape of the RNAi molecules, can be used in medium containing serum, and 
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did not form as many large non-functional, and potentially toxic, aggregates [63-65]. As 
outlined in Materials and Methods, we took both toxicity and other considerations into 
account [60] and the LF2K toxicity in our experiments was further decreased by reducing 
the amount of LF2K used without affecting siRNA silencing capacity (Appendix 1, Figure 
36).  
Large strides have been made towards overcoming the challenge of siRNA delivery in 
vivo with numerous new and inventive mediators of delivery [56, 66-69]. In 2010, Mark 
E. Davis and colleagues conducted the first-in-human phase I clinical trial involving the 
systemic administration of siRNA using a delivery vehicle to patients with solid cancers. 
They used a cyclodextrin-based, human transferrin protein-targeted nanoparticle 
delivery system and provided proof of an RNAi-mediated (RISC-mediated) mechanism of 
gene silencing in humans as a result of action of the administered siRNA [70, 71]. Carrier 
vehicles and formulation are not the only means of improving RNAi delivery; 
administration of small molecule drugs can also be augmented by a variety of delivery 
platforms (liposomes, penetrating-peptides, nanogels, etc.) to increase safety, potency, 
tissue permeability, and target delivery to the sites of tumours [72-75]. 
1.1.2.4 Characteristics of a good siRNA sequence 
While the seed region, already discussed above, is vitally important to siRNA on-target 
specificity, other key characteristics have been proposed as important to maximize 
effectiveness and specificity of siRNAs [76]. These key characteristics are summarized in 
Table 1, and function to optimize potency and effectiveness while decreasing non-
specific side-effects associated with the sequence and concentration [30]. As 
information increased, algorithms were developed and are updated to aid industry in 
the creation of optimized, targeting siRNAs [27, 76-78]. 
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Table 1. Characteristics of highly specific and potent siRNAs with reduced off-target 
effects. 
 
Characteristic Design/Rational Additional 
References 
GC content between  
30-52% 
Duplexes may have difficulty unwinding (RISC entry) when 
GC content is greater than 52%. Reduced interaction with 
mRNA recognition site when GC content is below 30% 
[76, 79, 80] 
Lack of siRNA 
secondary structure 
formation 
Interference with the formation of stable siRNA duplexes 
during synthesis, RISC incorporation, and target mRNA 
recognition 
[76, 79, 81] 
Asymmetry in siRNA 
duplex antisense 
strand selection by 
RISC  
5’-end of the antisense siRNA strand should have lower 
thermodynamic stability vs. passenger strand. Biases for A 
residue, and against C or G residues, at position 19 of 
passenger strand facilitate looser binding at the 5’-end of 
antisense strand and promotes uptake into RISC. 
[78, 82, 83] 
Specific base 
position biases 
within the sense 
strand (or target 
mRNA) 
Bias towards an A at positions 3 and 19,at least 3 “A/U” 
bases at positions 15-19, and a U at position 10. Bias  
against a G at position 13 and a G or C at position 19 of the 
sense strand. These biases may be important for efficient 
mRNA cleavage, which might involve binding to the target 
mRNA, cleavage itself, or recycling of the activated RISC. 
Ago2 has a bias toward cleavage at position 10 when a U is 
present; though it can still cleave after any nucleotide.  
[76, 79] 
Lack of direct 
immunostimulatory 
sequences within 
the siRNA 
Several sequences have been identified that will activate 
TLRs in a sequence-dependent (instead of general 
independent) manner (e.g. 5’-UGUGU-3’ or  
5’-GUCCUUCAA-3’) 
[50, 84, 85] 
Avoidance of 
sequences with 
known homology to 
unintended targets -
-- 
3’UTR 
complementarity 
with unintended 
targets increases 
off-target silencing 
Sequence-dependent off-target effects should be kept to a 
minimum via use of bioinformatics searches (e.g. BLASTn 
or Smith-Waterman dynamic programming sequence 
alignment algorithm). In particular, avoid sequences that 
have a completely or nearly complete complementary seed 
sequence (nucleotides 2–8 of the guide strand). Sequence-
independent chemical modification of siRNA RNA bases 
may help to reduce these effects. 
 
[26, 28, 77, 
86, 87] 
Lack of secondary 
structure at that 
target site 
Secondary structure in the complementary region of the 
target mRNA could result in decreased RISC mediated 
cleavage. However, because siRNAs are part of the RISC 
ribonucleoprotein complex which has putative helicase 
activity, secondary structure may not be as important for 
activity. Avoidance of tandem repeats within the RNA so as 
to prevent the possibility of hairpin-loop formation. 
[76, 81, 88] 
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1.1.3 siRNA and RNAi in treatment of human diseases 
Perhaps the greatest potential of RNAi is as a therapeutic in the treatment of diseases. 
RNAi molecules would broaden the scope of what can be targeted for therapeutic 
purposes; targets exist that are considered to be undruggable (i.e., not amenable to 
attack by small-molecule drugs and antibodies, which are constrained by their need to 
bind to enzyme active pockets or exposed epitopes) [37]. If RNAi molecules could be 
used successfully in vivo, the entire spectrum of the proteome could become 
“druggable” through reduction of RNAs responsible for production of those proteins; 
the sequence specificity of Watson-Crick base pairing between RNAi and target RNA 
should, in theory, produce a highly specific means of reducing both RNA and the 
products encoded by the RNA and/or generated by direct or indirect action of non-
coding RNA. siRNA and RNAi molecules are attractive candidates for treatment of 
cancer, retinal degeneration, viral infections, respiratory disorders, and genetic 
disorders with well-characterized mutations, such as muscular dystrophy, Down 
syndrome, and cystic fibrosis [68, 89].  
Along with the challenges mentioned above, there are other barriers to the successful 
use of siRNA, and RNAi molecules, in vivo that include: biological barriers (e.g., tissue 
penetrance and intracellular delivery and trafficking), toxicities of RNAi (e.g., reaction to 
delivery vehicle, RISC saturation), tissue specificity (e.g., healthy versus diseased tissue), 
pharmacokinetics and pharmacodynamics, and potential resistance to RNAi (e.g., 
inherent resistance based on genetic variations between different ethnic groups in allele 
frequency and/or SNPs, as well as altered RNAi processing machinery) [37, 90-92]. 
Despite these issues, there are a number of RNAi molecules currently in clinical trials, 
summarized in Table 2. While no RISC-mediated RNAi molecules have currently been 
approved for use in the clinic, a few of the more well-established oligodeoxynucleotides 
(ODNs), a form of RNAi that utilizes RNase H for mRNA cleavage, have advanced into 
clinical trials and some have also been approved for treatment of human disease [54]. 
These approved ODNs are Mipomersen (approved in 2013, which targets apolipoprotein 
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B-100 and is used to treat familial hypercholesterolemia) and Vitravene (which targets 
CMV IE2 (cytomegalovirus immediate early protein 2) protein and is used to treat 
retinitis caused by CMV in HIV-infected patients; approved in 1998 and since withdrawn 
due to lack of use) [54, 93-97]. 
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 Table 2. siRNAs in human clinical trials.  
This table was compiled using information contained at clinicaltrials.gov and [29, 61, 98, 99]  
 
siRNA Drug 
Name 
Disease Disease 
Category 
Target Phase Company 
Bevasirnaib Age-related 
macular 
degeneration 
(AMD) and macular 
edema (ME) 
Ophthalmology VEGF III 
(AMD), 
II (ME) 
Opko Health 
PF-4523655 
(PF-665) 
(diabetic) AMD and 
ME 
Ophthalmology RTP801 
(DDIT4) 
II (AMD 
& ME) 
Quark 
Sirna-027 
(AGN211745) 
AMD Ophthalmology VEGF-R1 I/II Allergan 
QPI-1007 Chronic optic never 
atrophy (NAION) 
Ophthalmology proNGF, 
caspase2 
I Quark 
TD1010 Pachyonychia 
congenita 
Genetic 
disorder 
Keratin K6a Ib International 
Pachyonychia 
Congenita 
Project 
Proteosome 
siRNA 
(iPsiRNA) 
Metastatic 
lymphoma and 
melanoma 
Oncology Immuno-
proteosome B-
subunits  
I Duke 
University 
CALAA-01 Solid tumours Oncology M2 subunit of 
ribonucleotide 
reductase 
I Pharmaceutica
l Inc. 
Atu027 Solid tumours 
(gastrointestinal, 
lung) 
Oncology PKN3 I Silence 
Therapeutics 
AG 
ALN-VSP02 Solid tumours 
(liver) 
Oncology KSP and VEGF I Alnylam 
I5NP 
(QPI-1002) 
Delayed graft 
function and acute 
kidney 
inflammation 
Inflammation p53 II Quark 
PRO-040201 Hypercholester-
olemia 
Metabolic 
disease 
ApoB I Pharmaceutica
ls Corp. 
ApoB SNALP Hypercholester-
olemia 
Metabolic 
disease 
ApoB I Tekmira 
ALN-RSV01 Respiratory 
Syncytial Virus 
(RSV) 
Viral infection RSV 
nucleocapsids 
II Alnylam/Cubist 
siG12D 
LODER 
Solid tumours 
(pancreatic 
adenocarcinoma) 
Oncology KRAS I Silenseed Ltd. 
ALN-TTR02 Transthyrein (TTR)-
mediated 
amyloidosis 
Genetic 
disorder 
TTR II Alnylam/Genzy
me 
SLY040012 Intraocular 
pressure 
Ophthalmology ADRB2 II Sylentis 
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1.1.4 Combinatorial RNAi 
Several properties of RNAi activity must be considered when using RNAi molecules in 
combination. For example, RNAi substrates (such as miRNAs, shRNAs and siRNAs) can 
compete with each other for RISC incorporation and processing [100]. In addition, the 
RNAi pathway is saturable, containing rate-limiting components such as Exportin-5 [101] 
and TRBP [15, 102] and Ago2 [103]. Exportin-5 is particularly important in regard to 
miRNAs and shRNAs, which require it fornuclear export [100, 101]. Oversaturation of 
Exportin-5 in the RNAi pathway with excessive miRNA/shRNAs resulted in mortality in 
mice due to severe liver toxicity [104]. TRBP is important for all double-stranded RNAi 
substrates as it acts as a sensor for selection and incorporation of the antisense guide 
strand into RISC [15, 100, 105]. Oversaturation of the RNAi pathway results in 
modulation of endogenous miRNA pathways important in cell growth, differentiation, 
and death [104]. This highlights the importance of ensuring that the RNAi pathway is not 
oversaturated in in vitro and in vivo studies and that shRNAs inherently carry an 
augmented risk of saturation over siRNAs (which bypass the necessity of Exportin-5 and 
other upstream RNAi processing enzymes). 
Combining multiple siRNAs targeting different RNAs in the same cell is relatively novel. 
Previous studies have not focused on combining multiple siRNAs, but various 
combinations of two of the following with or without concurrent drug treatment have 
been reported: ODN, siRNA, miRNA and shRNA [106-108]. The concept of an antisense 
siRNA cocktail to downregulate multiple targets has been more actively pursued for 
treatment of virally-induced human diseases than for treatment of cancer [89, 106, 
109]. In a very rare example, Chen et al. experimented with using 7 different siRNAs to 
simultaneously target multiple viral genomic components as a potential treatment for 
Hepatitis B [110]. 
Competitive inhibition upon combining several distinct siRNAs can result in a loss of 
silencing activity. The capacity of a given siRNA to interfere with the ability of another 
siRNA to downregulate its target mRNA is referred to as competition potency [111]. 
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Factors contributing to a given siRNA’s competition potency, whether it itself is a 
targeting siRNA or non-targeting siRNA (i.e., where there are no known sequences with 
sufficient complementarity in cells in which they are applied to mediate silencing), have 
not been solidly determined. Work in the field has focused on the chemical makeup of a 
given siRNA that may contribute to silencing efficiency, silencing potency, competition 
potency and, more recently, modifying the concentration of a given siRNA when using it 
in combination with other siRNA(s) [111-114].  
Combining multiple siRNAs targeting different mRNAs into one treatment is an 
especially intriguing idea for anticancer therapy, where use of drug cocktails in 
chemotherapy regimens is routinely applied in order to have an effect on several 
cancer-related proteins at the same time. While one would generally attempt to mix 
multiple different siRNA duplexes together to achieve this, Tiemann et al. took an 
approach significantly ahead of its time (given the field) and created a prediction 
algorithm fordual-targeting siRNAs in which both strands of the siRNA duplex stand a 
50:50 chance of being incorporated into RISC and where each is completely 
complementary to different mRNA transcripts; dual targeting siRNA were subsequently 
created, tested, and found to mediate target mRNA downregulation [115].  
1.2 Cancer: A general introduction to cancer and cancer treatments 
1.2.1 What is the problem and how big is it? 
The Canadian Cancer Society estimated that in 2013 there would be 187,600 new cases 
of cancer diagnosed, that the general probability of developing cancer would be 2 in 5 
Canadians, and that 75,500 deaths from cancer will occur during this same year. 
Consequently, cancer is the leading cause of death in Canada accounting for 
approximately 30% of all deaths [116, 117]. There are risk factors associated with the 
potential development of cancer, some of which are modifiable, including: age 
(increased incidence in people over 50 years of age), genetics (e.g., a family history of 
cancer/inherited cancer risk, BRCA gene mutations, and sporadic mutations), poor diet, 
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lack of physical activity, obesity, exposure to radiation (including sunlight), alcohol, 
infection with certain bacteria and viruses (e.g., Hepatitis C virus and human 
papillomavirus), smoking (including frequent exposure to second-hand smoke), and 
exposure to other environmental risks (e.g., asbestos, pesticides, and geographic 
location, both within and between countries) [116, 117]. There is an urgent need for 
better treatment options as cancer represents a significant global crisis and is a 
substantial burden to the Canadian population and healthcare system. Canada is a 
developed country with a cancer incidence greater than the global average, though 
incidences in poor and developing countries are quickly increasing [118-120]. 
1.2.2 The origins of cancer: Cancer as a disease of uncontrolled cellular proliferation 
Cancer is not one disease, but rather a term that can be applied to a diverse group of 
diseases sharing the common characteristic of abnormal, uncontrolled, cell division. 
These uncontrolled cells eventually form tumours (a mass of these cells) within a 
particular organ and which may eventually progress to form malignant tumours 
(tumours that invade or spread throughout the original organ and to nearby organs or 
other distant sites within the body)[121]. The underlying causes of transformation from 
“healthy cell” to “cancerous cell” are immense in number, and it is uncommon for any 
two cancer types to share exactly the same underlying deviations that permit cancer 
development, survival of the tumour, and increased morbidity and mortality in cancer 
patients.  
Nevertheless, some broad generalizations can be attributed to cancer cells and these 
were eloquently summarized by Hanahan and Weinberg in their 2000 and 2011 
“Hallmarks of Cancer” reviews. The hallmarks of cancer (including emerging hallmarks) 
have been described as: 
1) Sustained proliferative signalling  
2) Deregulated cellular energetics 
3) Resistance to cell death 
4) Genome instability and mutation 
5) Induction of angiogenesis 
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6) Active invasion and metastasis 
7) Tumour-promoting inflammation 
8) Replicative immortality 
9) Avoidance of immune destruction 
10) Evasion of growth suppressors 
 
The overarching theory is that cancer begins with mutations within the DNA of the cell’s 
genome (activation of oncogenes and/or inhibition of tumour suppressor genes). These 
mutations accumulate at such a rate that they go unrepaired (or occur in a DNA repair 
enzyme leading to decreased capacity to repair mutations occurring at relatively low 
rates) and confer a mutant phenotype onto the cell which provides it with the ability to 
replicate and reproduce chaotically, often in the face of signaling to the contrary. 
Through the hallmarks described above, cancer cells gain a proliferative advantage over 
the surrounding non-cancerous cells within their environment, domination of their 
surroundings (i.e., acting autonomously and without regard for the viability and function 
of normal surrounding cells), and capacity to accumulate, over time, progressively more 
malignant characteristics. 
1.2.3 Cancer as a metabolic disease: The Warburg and Crabtree hypotheses 
From the 1920s through the 1950s, Otto Warburg advanced and revolutionized the field 
of tumour cell metabolism. He demonstrated that tumour cells, compared to normal 
cells, prefer to metabolize glucose by glycolysis rather than respiration even in the 
presence of sufficient oxygen [122]. He then went on to postulate that tumorigenesis 
occurs through cellular defects in mitochondrial respiration that cause the cell to adopt 
glycolysis as a means to survive; that cancer is initiated by respiratory impairment and 
increased glycolytic rate occurs as a result [122-124]; this became known as the 
Warburg Effect and Warburg Hypothesis. 
Around the same time as Warburg’s initial discoveries in the 1920’s, Herbert Crabtree 
demonstrated and argued an alternative explanation for Warburg’s observations. 
Carbtree demonstrated that, in both normal and cancerous cells, increased glycolysis 
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inhibited respiration and suggested that this explained the deceased respiration noted 
by Warburg in tumour cells but, that actual defects in respiration were not the cause of 
the increased glycolysis [125, 126]; this became known as the Crabtree Effect and 
Crabtree Hypothesis. It is important to note that the Crabtree Effect does not actually 
explain the difference in magnitude between glycolysis in cancer cells as compared to 
normal cells and for this reason Warburg’s hypothesis became predominant in the 
cancer field even though a direct casual relationship has not been definitively 
elucidated.  
We are now aware that the relationship between cancer and metabolism, specifically 
with respect to glycolysis, is a complex one and below are some points that highlight 
this diverse phenomenon and opportunities which may also be exploited for cancer 
therapy [127]:  
I. altered metabolism is selected for by the tumour microenvironment: Tumours 
experience hypoxic conditions when they outgrow their local blood supply and  
decreased reliance upon respiration and increased reliance upon glycolysis is 
advantageous - changes in hypoxia-inducible factor (HIF) and vascular 
endothelial growth factor (VEGF) occur [128, 129] 
II. the activation of certain oncogenes can drive changes in cell metabolism: For 
example, oncogenic K-ras promotes metabolic changes in glucose metabolism 
and elevated glucose uptake consistent with a K-ras-mediated increase of  
glycolysis in tumours [130, 131] 
III. lactate produced and secreted by cancer cells from increased glycolysis may serve 
to support cancer cell survival, invasion, metastasis and immune evasion: For 
example, in in vitro experiments, lactic acid suppressed the activity of human 
cytotoxic T lymphocytes (proliferation by up to 95% and killing by up to 50%) and 
activity was restored when cells were allowed to recover in lactic acid free 
medium [132, 133] 
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IV. that altered metabolism may serve to support macromolecule biosynthetic 
pathways: Proliferating cells require not only ATP but, also amino acids, 
nucleotides and fatty acids to support the increased demand on macromolecular 
synthesis for cellular replication. A function of increased glycolysis in rapidly 
proliferating cells may be to provide high levels of glycolytic intermediates 
capable of supporting biosynthetic pathways [134, 135]. Glycolysis is a major 
source of carbons (5 to 9 carbons out of a required 10) for nucleotide 
biosynthesis [134]. 
It is important to note, that often, the Warburg hypothesis is interpreted to mean that 
glycolysis occurs instead of respiration; that damage to respiration is thought to occur 
instead of deregulation of glycolyis. However, many tumour have been shown to 
demonstrate the Warburg effect (glucose fermentation) while still performing 
mitochondrial respiration (glucose oxidation) [136]. Part of the confusion stems from 
Warburg’s initial misinterpretation of his own early data and which was later clarified -
relative to their consumption of glucose.  Indeed, the respiration of cancer cells is low 
but, it is not low in comparison to the respiration of normal cells; in fact the high glucose 
consumption rate is used for tumour visualization via positron emission tomography 
(PET) [135, 136]. This means that respiration and mitochondria can still play important, 
functional, roles in cancer cells even when glycolysis is increased.  
1.2.3.1 Relevance of mitochondria and mitochondrial DNA (mtDNA) in cancer 
Recall that mitochondria are sub-cellular organelles producing ATP through oxidative 
phosphorylation (OXPHOS) and playing an important role in the control of cellular 
apoptosis. Deregulation of mitochondria does not explain the Warburg effect, however, 
there is strong evidence that defective mitochondria do accumulate in tumours [137]. 
Oncogenes and tumour suppressor genes can influence mitochondrial mass (which, in 
healthy cells, is proportion to cell size and energy demands) by having downstream 
effects on mitochondrial biogenesis (formation) and mitophagy (intracellular 
mitochondrial turnover or degradation); this make sense as mitochondrial biogenesis 
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involves replication of the mitochondrial genome which is a coordinated effort between 
mitochondrial and nuclear genome encoded proteins [135, 138]. For example, members 
of the Bcl-2 superfamily, regulators of cell death, have a role in both the regulation of 
apoptosis and in mitochondrial fission and fusion dynamics (important in responding to 
energy demands during cellular stress); indicating a interrelated fluidity to 
mitochondrial cell death and energy functions and highlighting Bcl-2 family members as 
potential anticancer targets [137, 139]. 
The mitochondrial genome is 16,569 bp large and encodes 13 distinct proteins which are 
primarily involved in the synthesis of the electron transport chain (ETC) for the OXPHOS 
production of ATP. Each mitochondrion typically contains 2 to 10 copies of 
mitochondrial DNA (mtDNA) and each cell has, on average, 1000 mitochondria resulting 
in thousands of mtDNA genomes/copies per cell [140]. Mutations within the 
mitochondrial genome have been reported in cancers of the pancreas, breast, prostate, 
bladder, thyroid and colon (see Chatterjee et al. [141] for a review of cancer sites and 
associated mutations in mtDNA). The mitochondria contribute to the formation of 
reactive oxygen species (ROS) within the cell via leakage of electrons from the ETC. An 
increase in ROS, that cannot be balanced by antioxidants, can result in oxidative stress, 
(implicated in a variety of pathologies including aging and cancer) that can lead to the 
oxidation of proteins, lipids, and nucleic acids such as nuclear DNA (nDNA) and mtDNA; 
thus, mitochondria serve not only as source of ROS but also as a target of ROS [142-
144].For example, mitochondrial-produced ROS can contribute to mtDNA and nDNA 
mutations, which can then lead to further cellular deregulation and increased ROS 
production in a circuitous cycle involving damage to mtDNA and ETC components [142, 
145].       
mtDNA alterations and copy number changes may also have a diagnostic value in human 
cancers. qPCR can be used to evaluate quantitative variations in mtDNA content. Many 
cancer types have shown either increased mtDNA content (acute lymphoblastic 
leukemia, colorectal, head and neck, ovarian, etc.) or a decrease in mtDNA content 
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(breast, non-small cell lung cancer, hepatocellular carcinoma, etc.) and chemotherapy 
resistant phenotypes have been associated with both increased and decreased mtDNA 
in cancers of the head and neck and colon [146-150]. Studies of mtDNA content in 
human tumours have shown that there is some degree of stability in the range of 
mtDNA copy number (within 2-fold) for a particular tumour type or primary site when 
compared to the content in normal surrounding tissue [151, 152]. As numerous studies 
have made an association between mtDNA copy number and cancer risk and/or disease 
progression, mtDNA copy number variations are being explored as a novel biomarker for 
human cancers [146, 153-157]. mtDNA can be easily detected from bodily fluids (e.g. 
whole blood, saliva, urine) and as such, monitoring mtDNA copy quantitative changes is 
a potentially non-invasive method for screening pre-malignant lesions and high-risk 
individuals along with monitoring or charting cancer progression, identifying disease 
recurrence and predicting prognosis. 
1.2.3 The treatment of cancer 
Current anticancer treatments can be broken down into three general categories; 
surgery, chemotherapies, and radiation [118, 158]. Typically, cancer treatment will 
involve a combination of these categories and/or multiple agents within a given 
category so as to do battle with cancer on multiple fronts; for example, combined drug 
cocktails such as R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine 
and prednisone) in the treatment of lymphoma [159, 160]. The determination of what 
treatment(s) a patient receives depends upon the location, size, and severity of the 
disease, as well as characteristics of the individual (age, state of health, treatment 
preference and, when known, specific characteristics of the tumour that can modulate 
sensitivity to treatment i.e. personalized medicine) [118]. Further discussion of cancer 
treatments will focus exclusively on thesis relevant chemotherapies. 
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1.2.3.1 Drugs used in cancer chemotherapy 
Chemotherapeutics used during experimentation in this thesis include 5FUdR, 
pemetrexed, cisplatin and gemcitabine. As both 5FUdR and pemetrexed are thymidylate 
synthase (TS) inhibitors, they will be discussed in the next section under inhibitors of TS. 
Directly below will be a brief discussion regarding cisplatin and gemcitabine. Cisplatin is 
used in chapter 3 as a non-TS-targeting drug for the purposes of an experimental 
control. Gemcitabine is used in experiments described throughout that chapter.  
1.2.3.1.1 Cisplatin 
Cisplatin (or cis-Diamminedichloroplatinum(II), CDDP) is a platinum-based anticancer 
drug that exerts its cytotoxicity via the cross-linking of DNA to form platinum (Pt)-DNA 
adducts which accumulate and ultimately cause apoptosis [161, 162]. While highly 
effective against multiple cancers (tesicular, overian, bladder, colon, etc.), until 
resistance develops, cisplatin is also associated with severe nephro- and neuro- and oto-
toxicity which, may be partly reversible but are also therapeutically limiting [163].  
Resistance to cisplatin may be intrinsic or acquired after a patient exposure. Resistance 
mechanisms include alterations in pharmacokinetics (i.e. decrease drug accumulation, 
increased drug efflux, increased detoxification), increased DNA repair (i.e. over 
expression of nucleotide excision repair enzymes) and increased tolerance to cisplatin-
induced damage (i.e. reduced apoptotic response) [164, 165].  
1.2.3.1.2 Gemcitabine 
Gemcitabine (2’, 2’-difluoro 2’deoxycytidine, dFdC) is a deoxycytidine analogue that is 
used to treat a wide variety of tumour types (lung, breast, ovarian, bladder and 
pancreas) [166]. Gemcitabine is a pro-drug that is activated intracellularly via 
phosphorylation by deoxycytidine kinase (dCK) to gemcitabine monophosphate and 
subsequently processed into di- and tri- phosphorylated forms which are active 
metabolites in mediating an anti-tumour response [166, 167].  Ridonucleotide 
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reductase, the enzyme responsible the production of nucleotides for DNA synthesis and 
repair, is inhibited by gemcitabine diphosphate and contributes to gemcitabine 
cyototoxicity [168, 169]. Tri-phosphorylated gemcitabine (dFdCTP) exerts cytotoxicity by 
a mechanism known as masked chain termination (MCT) which inhibits DNA synthesis 
and eventually results in apoptosis [166, 170]. Briefly, in MCT, dFdCTP is recognized as a 
“normal” nucleotide and incorporated into DNA. However, once incorporated it 
prevents further DNA chain elongation and inhibits DNA synthesis as only one additional 
nucleotide can be added by DNA polymerases to the growing DNA chain (this is the 
“masking” part). Polymerase exonuclease activity and DNA repair mechanisms are 
ineffective at detecting, removing, and replacing dFdCTP and apoptosis results from lack 
of DNA synthesis. Resistance can result due to increased drug efflux, decreased 
intracellular uptake, genetic polymorphisms in patients and decreased pro-drug 
conversion into active metabolites [171-173]. 
1.3 Enzymes that synthesize deoxythymidine monophosphate (dTMP) 
1.3.1 De novo synthesis of dTMP by thymidylate synthase 
Thymidylate synthase (TS) is the enzyme responsible for de novo synthesis of 
deoxythymidine monophosphate (dTMP or thymidylate) via the reductive methylation 
of deoxyuridine monophosphate to dTMP using methylene tetrahydrofolate (CH2THF), a 
folate co-factor, as the methyl donor [174]; this has previously been referred to as the 
thymidylate synthesis cycle (Figure 2) [175]. The enzyme is highly conserved and 
functions as a homodimer comprised of 35kDa subunits[174].  
The TS enzyme is an essential enzyme for the production of dTMP used in DNA 
synthesis/replication (Figure 2). It plays an important role in cellular proliferation and 
has been a invaluable drug target in the treatment of cancer since the late 1950’s with 
the introduction of 5-fluorouracil (an antimetabolite, nucleoside analogue to be 
discussed more below) [176, 177].  
  
 
 
Figure 2: Thymidylate synthesis cycle and dTTP incorporation into DNA
TS catalyzes the reductive methylation of dTMP from dUMP using CH
dihydrofolate is generated as a biproduct in a 1:1 ratio with dTMP. Using NADPH, DHFR 
regenerates THF. THF is then converted back into CH
generate dTMP. Once dTMP is generated, it is then become di
which is incorporated into DNA during synthesis and repair. 
SHT, serine hydroxyl transferase; THF, tetrahydrofolate; DHF, dihydrofolate; dTDP, 
deoxythymidine diphosphat
 
2THF as the methyl donor; 
2THF by SHT to be used again by TS to 
- and tri-phosphorylated into dTTP 
 
e; dTTP, deoxythymidine triphosphate 
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1.3.1.1 Regulation of TS protein expression 
TS expression and activity is cell cycle-dependent, being highest during S phase and 
decreasing by G2 [178-181]. It has been observed that rapidly proliferating cells in 
general have increased levels of TS compared to those cells in G0, and that human 
tumour cells have variably higher levels of TS than normal, non-tumour proliferating 
cells [180, 182]. TS enzyme levels are tightly regulated at the level of translation. The TS 
protein can bind to its own mRNA to inhibit translational processing of the mRNA - 
termed translational repression and specifically autoregulation [183, 184]. Exogenously-
administered allosteric inhibitors of TS (including anticancer drugs that target TS) bind 
to the protein and suppress it's capacity to generate thymidylate but, in doing so, can 
also suppress the capacity of TS to repress translation of its own mRNA: the resulting 
translational derepression induces a transient two-fold to four-fold increase in TS 
enzyme levels, shown both in vitro and in vivo, including in human patients [185-189]. 
The transient TS increase counters the intended therapeutic effect of TS-targeting drugs 
and is a significant clinical problem. Hence, TS has a dual function: it is both an enzyme 
and a regulatory feedback molecule, capable of modulating its own level by mediating 
translation of its own mRNA. In addition to binding its own mRNA, TS has also been 
shown to bind to, and inhibit the translation of, the mRNAs of both c-myc and p53 [190-
193]. These data suggest a role for TS in the translational regulation of other proteins in 
addition to its self-regulatory function [194].  
1.3.1.2 TS and cancer 
As an important enzyme in DNA synthesis and replication, TS has had a lengthy, 
intimate, and intertwined relationship with cancer research and cancer treatment. 
Elevated TS levels in maligancy, at a plethora of body sites, have been well established 
since the 1950s [176, 182, 195-197]. Elevated TS levels in multiple human tumour types 
have been correlated with cancer progression, poor prognosis, and poor response to 
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treatment [187, 188, 198-201]. Specific inhibitors of TS and the development of 
resistance to treatment are discussed below. 
1.3.1.3 TS enzyme inhibitors 
The following sections focus on TS inhibitors used in experiments described in this thesis 
(5FU, 5FUdR, and pemetrexed).  
1.3.1.3.1 dUMP analogues 
TS is an important enzyme with respect to cancer and drugs targeting TS-protein have 
been a mainstay in cancer chemotherapy since the synthesis of fluorinated pyrimidines 
[177, 195]. Fluorinated pyrimidines including 5-fluorouracil (5FU) and 5-
fluorodeoxyuridine (5FUdR) belong to the nucleoside analogue class of drugs and inhibit 
TS by mimicking dUMP and irreversibly binding the enzyme. 5FU is a uracil analogue 
with a fluorine atom introduced in place of hydrogen at the carbon-5 position, used in 
the treatment of cancers of the breast, and colon. Once inside the cell, the 5FU prodrug 
is converted to metabolites (5FUdR) and active metabolites (fluorodeoxyuridine-
monophosphate and -triphosphate, FdUMP and FdUTP). FdUMP binds to and inhibits 
the capacity of TS to produce dTMP, resulting in dTMP and dTTP pool depletion. 
Thymine-less death results from the subsequent disruption of DNA synthesis and repair 
as dUTP is inappropriately incorporated into DNA, resulting in cell death [202-205].  
1.3.1.3.2 Antifolates 
A second class of TS inhibitors are folate analogues, such as pemetrexed, which target 
TS by blocking its use of CH2THF as a co-factor in the production of dTMP [201, 206]. 
Pemetrexed is, in fact, a multi-targeting antifolate analogue that inhibits 
dihydrodofolate reductase (DHFR) and glycinamide ribonucleotide formyl transferase 
(GARFT) in addition to inhibiting TS as its primary pharmacological target [207]. 
Thymine-less death is similarly thought to be an important contributing factor to the 
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mechanism of pemetrexed-induced cell death, along with a general depletion of purines 
associated with DHFR and GARFT inhibition [208].  
1.3.1.4 Resistance to TS-targeting drugs 
TS-targeting drug-induced increases in TS levels within tumour cells is a mechanism of 
resistance to TS-targeting chemotherapies [187, 188]. TS levels can increase in tumour 
cells in the presence of TS inhibitors due to translational derepression and/or enzyme 
stabilization [195, 209, 210]. In addition, TS increases are mediated by TS gene 
amplification and patients with increased levels of TS enzyme have been shown to have 
a poor prognosis [197, 198, 205, 211-214]. Increased levels of TS protein in tumour cells 
provide "sacrificial targets" for anti-TS chemotherapeutic drugs, increased capacity to 
withstand exposure to those drugs, and decreased likelihood of suffering the 
consequences of preferential tumour-associated, chemotherapy-induced toxicity (i.e., 
apoptosis, necrosis, growth arrest). For the above reasons, it is imperative that new 
anti-cancer therapies be developed to specifically overcome TS overproduction (and 
associated chemotherapy resistance) in human tumour cells. An attractive strategy to 
do so includes the use of antisense molecules targeting TS, either as single agents or in 
combination with small molecule drugs that target TS protein. The Koropatnick 
laboratory has demonstrated this to be a valuable approach to improve the 
effectiveness of TS-targeting drugs, both in vitro and in in vivo animal models [215-219].  
Along with increased TS, the thymidine kinase salvage pathways (discussed below) that 
contribute to alternative dTMP production are also contributors to resistance to TS-
targeted drugs [220, 221].  
1.3.2 Salvage synthesis of dTMP by thymidine kinases 
1.3.2.1 Thymidine kinases 
There are two thymidine salvage enzymes in the cell that produce dTMP by ATP-
dependent phosphorylation of deoxythymidine: cytosolic thymidine kinase 1 (TK1) and 
27 
 
mitochondrial thymidine kinase 2 (TK2). TK1 and TK2 are different proteins that both 
phosphorylate endogenous and exogenous (imported by nucleoside transporters) 
thymidine to produce dTMP necessary for DNA synthesis and repair. They have different 
patterns of expression in tissues and intracellular localization (to be discussed in more 
detail below) and are encoded by different genes located on different chromosomes 
(TK1 on chromosome 17 and TK2 on chromosome 16) [222]. Both TK1 and TK2 activity 
and expression are negatively regulated via feedback inhibition of their downstream 
phosphorylation products - mainly by high levels of dTTP (and dCTP, for TK2 as well) 
within the cell[222, 223].  
1.3.2.1.1 Thymidine kinase 1 (TK1) 
TK1 is a cytosolic, cell cycle-dependent enzyme that functions primarily as a homodimer 
of two 25 kDa subunits[224]. It has an expression pattern similar to that of TS and 
activity and expression are high in proliferating cells, including malignant cancer cells, 
and absent in quiescent cells [225-227]. TK1 protein is regulated at the transcriptional 
level by E2F; at the translational level, potentially by its own mRNA; and at the post-
translational level (for example, rapid mitotic degradation via the anaphase-promoting 
complex) [224, 225, 228, 229]. TK1 has a more constrained preference for thymidine as 
a phosphorylation substrate than does TK2 (discussed below)[230]. 
1.3.2.1.2 Thymidine kinase 2 (TK2) 
Historically, TK2 is the least studied nucleoside kinase and information on the enzyme, 
especially compared to TK1, is lacking. Human TK2 is a 29-35 kDa, constitutively 
expressed, mitochondrial nucleoside kinase encoded by a nuclear gene with a half-life of 
around 33 h [231, 232]. In normal proliferating cells, TK2 activity is low (an estimated 1-
5% of total TK activity), but in quiescent, non-proliferating cells TK2 accounts for 100% 
of the TK activity [233, 234]. TK2 expression in different tissues has previously been 
shown to have a positive correlation with number of mitochondria [222]. Unlike TK1, 
TK2 displays substrate promiscuity in that it will phosphorylate thymidine, cytosine and 
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adenosine to fulfill the requirements of mitochondrial DNA replication and genome 
maintenance [235]. On the other hand, TK2 does not phosphorylate deoxyguanosine: 
that event is mediated, in mitochondria, by deoxyguanosine kinase [222, 230].  
1.3.2.2 TK1 and cancer 
Immunostaining for TK1 has confirmed its increased expression in a number of different 
cancers (those arising in breast, liver, lung, bladder, thyroid, and white blood cells) and 
increased serological TK1 levels have been correlated with increased malignancy and 
poor prognosis [236-243]. Upregulation of TK1 has been demonstrated both in vitro and 
in vivo in response to treatment with anticancer drugs and DNA damaging agents such 
as 5FU (a TS inhibitor) and doxorubicin [244-246], prompting speculation that TK1 could 
contribute to resistance to anticancer therapies. The relative ease of measurement of 
TK1 and the presence of elevated TK1 level in multiple human tumours has prompted 
assessment of TK1 in serum as a proliferation marker and screening tool to monitor 
cancer in the clinic with respect to prognosis, treatment, and detection of recurrence 
[236, 242, 246-250].  
In healthy replicating cells, de novo thymidylate synthesis pathways are thought to be 
capable of providing the necessary amounts of dTMP required for DNA synthesis. 
However, in cancerous and other rapidly dividing cells, the role and contribution of 
salvage enzymes may be greater [222]. It is possible that TK1 (and/or TK2), through their 
activity as mediators of salvage pathway production of dTMP, mediate resistance to 
small molecule drugs and antisense molecules capable of reducing TS activity and TS 
level, respectively. Unlike TS, there are currently no pharmacological agents targeting TK 
for the purposes of anti-cancer therapy., Thus, an antisense approach was taken in 
experiments described in this thesis, to reduce TS, TK1, and TK2, alone and in 
combination with each other, to determine the capacity of combined reduction of TS 
and TK to sensitize human tumour cells to current TS-targeting anticancer drugs. Given 
the greater contribution of de novo TS synthesis to dTMP production in cycling cells, we 
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expect the that reduction of TK1 or TK2 alone will be insufficient to sensitize to TS-
targeted chemotherapy.  
1.3.2.3 TK2 in human disease 
Mutations in, and dysregulation of, the TK2 gene are associated with a heterogeneous 
group of autosomal recessive disorders known as mitochondrial DNA depletions 
syndromes (MDS), specifically the myopathic forms (progressive muscle weakness) and 
encephalomyopathic form (stroke-like episodes, migraine headaches, seizure) [251-
254]. Mutations in genes that function in mitochondrial DNA (mtDNA) replication and/or 
mitochondrial dNTP synthesis result in impaired mtDNA and genome maintenance [253, 
255, 256]. A reduction in mitochondrial DNA (mtDNA) content leads to impaired energy 
production in the affected tissues and organs, and the leading hypothesis is that this is 
due to insufficient synthesis of mitochondrial electron transport chain components 
[255, 257, 258]. There is some evidence to show that the tissue specificity and severity 
of MDS resulting from TK2 dysregulation may be affected by the ability of TK1 and 
nucleotide transporter proteins to compensate for reductions in dTTP in mitochondrial 
dNTP pools [259, 260]. MDS can affect either a specific organ or combination of organs, 
which most often include muscle, liver, kidney and brain. TK2 associated MDS patients 
are predominantly pediatric and death occurs within a few years of diagnosis, resulting 
from rapidly progressing muscle weakness and respiratory failure [251, 254, 261-263].  
1.4 Project rationale 
Antisense targeting of TS in combination with TS-targeting small molecule drugs 
resulted in potentiation of inhibition of tumour cell proliferation and cell death. It is 
possible that the TK enzymes mediate resistance to TS-targeting small molecule drugs 
and/or -antisense. There are currently no pharmacological inhibitors of human TKs. 
Thus, a combinatorial RNAi approach (in which siRNAs against TS, TK1 and TK2 are 
combined in single treatments) was taken to investigate if one or both of the TK 
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enzymes may contribute to decreased effectiveness of TS targeting drugs (5FUdR and 
pemetrexed) and/or antisense siRNA molecules. 
As TK2 displays substrate promiscuity and contributes to levels of both dTMP and dCMP, 
it is possible that TK2 mediates resistance to the anticancer drug gemcitabine via 
feedback inhibition of the gemcitabine-activating enzyme dCK; this would be the 
downstream production of deoxycytidine triphosphate molecules by way of TK2-
produced dCMP. As small molecules inhibitors of TK2 are not commercially available (or 
available in sufficient quantities for experimentation at the start of this project), siRNAs 
targeting TK2 were used in combination with gemcitabine to address this question. 
Given that TK2 is a mitochondrial enzyme important for the synthesis and maintenance 
of mtDNA and that gemcitabine can negatively affect mitochondrial DNA polymerase y, 
changes in mtDNA content and activity where also monitored after exposure to 
combined TK2 siRNA and gemcitabine treatment to elucidate what impact, if any, there 
was on mitochondria.  
1.5 Hypotheses 
1. TKs mediate resistance to TS-targeting small molecule drugs 
2. TKs mediate resistance to the capacity of TS siRNA to sensitize tumour cells to 
TS-targeting anticancer drugs. 
3. TK2 can mediate human tumour cell resistance to gemcitabine, and antisense 
downregulation of TK2 can overcome that resistance. 
4. TK2 siRNA-induced drug sensitization causes increased mitochondrial damage. 
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Chapter 2  
« Materials and Methods »  
Details of the materials used and methods employed are taken from my already 
published paper in the Journal of Pharmacology and Experimental Therapeutics [264], 
with expanded information.  
2.1. Human tumour cell lines 
Human cervical carcinoma (HeLa), breast epithelial adenocarcinoma (MCF7), lung 
epithelial carcinoma (A549), mesothelioma (lung derived, Meso H28) and colorectal 
adenocarcinoma (HT-29) cell lines were purchased from the American Type Culture 
Collection (Manassas, VA and Rockville, MD, USA). HeLa and MCF7 cell lines were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Wisent Inc., St-Bruno, 
Quebec, Canada) supplemented with 10% fetal bovine serum (FBS; Gibco, Burlington, 
Ontario, Canada). A549 and HT-29 cell lines were cultured in Alpha MEM (AMEM) 
(Wisent Inc.) supplemented with 10% FBS (Gibco). Meso H28 cells were cultured in RPMI 
(Wisent Inc.) supplemented with 10% FBS (Gibco). All cell lines were maintained in a 
humidified incubator at 370C with 5% CO2 in air. Cultured cells were kept under 75% 
confluency at all times. 
2.2. siRNAs 
All siRNAs (ON-TARGET plus or siGENOME) were obtained from Dharmacon RNAi 
Technologies (Lafayette, CO, USA) as annealed and desalted duplexes. ON-TARGET plus 
siRNAs contain a chemical modification that enhances siRNA antisense strand entry into 
the RNA-induced silencing complex (RISC) for certain sequences (identified by 
Dharmacon’s siRNA design algorithm) where the modification is likely to enhance 
specific activity without increasing off-target binding [27, 77, 78, 87, 265]. ON-TARGET 
plus or siGENOME reagents were used as recommended by Dharmacon for each 
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targeted mRNA sequence (Table 3). All siRNAs were resuspended in siRNA buffer 
(supplied by Dharmacon) to generate 5 μM or 10 μM stock solutions. Throughout 
experiments, total siRNA concentration was held constant at 10 nM. C2 siRNA was used 
as a supplement when the combined concentration of targeting siRNAs was less than 10 
nM (Appendix 1). Results sections will indicate specific siRNA concentrations used. 
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Table 3: siRNA sequences.  
Control siRNAs (C2, C3) contain 4 or more mismatches with all known human RNAs. Cy3-
labeled TS siRNA #4 has the Cy3 fluorophore attached to the 5’ end on the antisense 
strand to avoid interference with the important seed region at the 3’ end.  
 
siRNA siRNA short-form Targeted 
RNA 
Target mRNA 
Sequence 
mRNA 
transcript 
ON-TARGETplus 
Non-targeting 
siRNA 
Control 2; C2 
C2 
 
 
No Target 5’-UGGUUUACA- 
UGUUGUGUGA-3’ 
 
ON-TARGETplus 
Non-targeting 
siRNA 
Control 3; C3 
C3 No Target 5’-UGGUUUACA- 
UGUUUUCUGA-3’ 
 
TYMS siGENOME 
siRNA TS siRNA #3 
CH 3. TS siRNA (1) TS mRNA 5’-ACAGAGAUA- 
UGGAAUCAGA-3’ 
576-594 
Coding region 
TYMS siGENOME 
siRNA TS siRNA #4 
CH 3. TS siRNA (2), 
CH 4. TS siRNA #4, or 
TS siRNA 
TS mRNA 5’-GGACUUGGG- 
CCCAGUUUAU-3’ 
526-544 
Coding region 
Cy3 labelled TS #4 
siRNA 
Cy3-TS siRNA 
Cy3-TS siRNA TS mRNA 5’-GGACUUGGG- 
CCCAGUUUAU-3’ 
526-544 
Coding region 
Human TK1 ON-
TARGETplus siRNA 
TK1 siRNA #11 
 CH3. TK1 siRNA (1), 
or TK1 siRNA 
CH4. TK1 siRNA 
 
TK1 
mRNA 
5’-GCACAGAGU- 
UGAUGAGACG-3’ 
308-326 
Coding region 
Human TK1 ON-
TARGETplus siRNA 
TK1 siRNA #12 
CH3. TK1 siRNA (2) TK1 
mRNA 
5’-CAAAGACAC- 
UCGCUACAGC-3’ 
578-596 
Coding region 
Human TK2 ON-
TARGETplus siRNA 
TK2 siRNA #9 
CH 3. TK2 siRNA (1), 
or TK2 siRNA 
CH 4. TK2 siRNA #9 
TK2 
mRNA 
5’-AAAUCGGGA- 
UCGAAUAUUA-3’ 
1101-1119 
Coding region 
Human TK2 ON-
TARGETplus siRNA 
TK2 siRNA #11 
CH 3. TK2 siRNA (2), 
CH 4. TK2 siRNA #11 
TK2 
mRNA 
5’-UCACAGCGC- 
AAGAUACAUU-3’ 
759-777 
Coding region 
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2.3. Cytotoxic drugs 
5FUdR was purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). 
Pemetrexed (Alimta, manufactured by Eli Lilly and Co., Toronto, Ontario, Canada), 
cisplatin (Platinol, manufactured by Bristol-Myers Squibb, Montreal, Quebec, Canada) 
and gemcitabine (Gemzar, Eli Lilly and Co., Toronto, ON, Canada) were obtained from 
the pharmacy at London Regional Cancer Program (London, Ontario, Canada). 
2.4. siRNA transfection 
2.4.1. General transfection methodology 
Twenty-four hours prior to siRNA transfection, cells were plated in NUNC 25 cm2 tissue 
culture flasks (T-25, Nunclon™ Δ surface)(VWR International, Ontario, Canada) in 2mL of 
medium supplemented with 10% FBS. The next day (approximately 24 h later), cells 
were transfected with 10 nM siRNA using Lipofectamine 2000 (LF2K or LFA2K, 
Invitrogen, Carlsbad, CA). Transfections were performed according to a modification of 
the manufacturer’s protocol that included a 50% reduction of the amount of LF2K used, 
which allowed for the same mRNA down regulation obtained when following the 
standard protocol, while decreasing off-target toxicity effects associated with LF2K (see 
Appendix 1 for supporting information). Briefly, equal volumes of LF2K mixture (120 μL 
serum-free medium and 5 μL LFA2K) were combined with siRNA mixture (total siRNA 
concentration of 10 nM when added to cells in serum-free media volume of 125 μL). 
Mixture was incubated for 20 mins to allow loading of liposomes with siRNA. 
Experimental conditions included untreated cells (NTC, only medium) and LF2K-treated 
cells (LF2K only without siRNA) as controls. After 20 mins, 250 μl of the combined 
mixture were added to each T25-flask. Four hours after transfection, one of the 
following was done to the flasks depending on the nature of the experiment.  
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2.4.1.1. Experiments lasting only 24h post-transfection with siRNA (not applicable to 
time course results) 
In these experiments, cells were initially plated at 1.5x105 cells/flask (HeLa) or 2.0x105 
cells/flask (MCF7). Four hours post-transfection, 4 mL of medium containing 10% FBS 
were added to each flask. Cells were harvested for analysis 20 h later. 
2.4.1.2. Experiments lasting longer than 24 h post-transfection with siRNA (including 
time-course and drug-treatment experiments)  
In these experiments, cells were initially plated at 3.5x105 cells/flask regardless of cell 
line used. Four hours post-transfection, cells were re-plated at specific densities (Table 
4), in triplicate flasks for the siRNA treatment conditions and the drug treated 
conditions. When cells were intended for analysis by immunoblotting or flow cytometry, 
6 x T25 flasks were re-plated for each drug-treated condition to allow 2 x T25 flasks to 
be pooled at random to ensure enough cells were available for analysis. Unless 
otherwise indicated, flasks were then incubated until the time of sample collection. 
When re-plating was required for the experiment and there was more than one flask per 
treatment group at time of transfection, the cells were pooled prior to re-plating. The 
pooling of cells from multiple flasks per specific treatment group and their re-plating at 
a lower cell density was done to carry cells for the length of the experiment without 
over-growth of controls and to maintain more consistent transfection conditions. 
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Table 4: Cell numbers and media volumes upon re-plating 
Analysis Method Cell Number Used for Re-
plating 
(cells/flask or well) 
Volume of Media for Re-
plating 
 
Cell Counting - Coulter 
Counter 
5.0 x 104  3 mL 
Immunoblots 
(end points are post 
transfection and re-plating) 
48 h end point = 1.5 x 105 
72 h end point = 1.0 x 105 
96 h end point = 5.0 x 104 
3 mL 
(4 mL when experiment did 
not involve gemcitabine) 
qPCR - mRNA or DNA 
(end points are post 
transfection and re-plating) 
24 h end point = 2.0 x 105 
48 h end point = 1.5 x 105 
72 h end point = 1.0 x 105 
96 h end point = 5.0 x 104 
3 mL 
(4 mL when experiment did 
not involve gemcitabine) 
alamarBlue assay 1.0 x 103 100 μL 
Flow Cytometry 5.0 x 104 3 mL 
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2.4.2. siRNA transfection with Subsequent Cytotoxic Drug Treatment 
When drugs were used, the cells were treated 4 h after re-plating as follows: 
i) The drug-untreated group received 1 mL of medium (when using T25 flasks 
or 6-well plates; 100 μL when using 96-well plates) 
 
ii) The drug-treated group received 1 mL of medium (when using T25 flasks or 
6-well plates; 100 μL when using 96-well plates) containing drug at the 
required concentration to yield indicated final concentration used in 
experiment  
Cells were incubated for the time required for each experiment and then collected for 
analysis. 
2.5. Measures of cellular proliferation 
2.5.1. Cell counting 
 The effects of siRNA treatment on cellular proliferation, alone or in combination 
with anticancer drugs, were assessed. Cells were exposed to various treatments, grown 
for 4 days, washed with PBS, trypsinized, and counted on a Beckman Coulter Z1 Particle 
Counter (Beckman, Mississauga, Ontario, Canada). Results were analyzed by calculating 
the fold change in cell number after 4 days of growth (relative to the starting number of 
plated cells) as: 
Fold Change  number of cells, day 4  number of cells, day 0number of cells, day 0  
Differences in proliferation induced by treatment were expressed as “% Fold Change” 
and were calculated using “Fold change” in cell number in treated cells (“treatment fold 
change”) and the fold change in cell number under appropriate matched control 
conditions (“control fold change”): 
% Fold Change   treatment fold changecontrol fold change  ! 100 
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2.5.2. alamarBlue assay 
After transfection, cells were re-plated into 96 -well plates. Each 96-well plate contained 
drug-untreated conditions as controls for the gemcitabine concentration(s) in that plate. 
Plates also contained wells with only medium supplemented with 10% FBS (no cells 
present, 200 uL) for assay background control.  
Ninety-six hours after re-plating, 100 uL of medium was removed from each well and 
replaced with 100 uL of a 1:10 dilution of alamarBlue reagent (Invitrogen, Carlsbad, CA) 
in medium containing 10% FBS (final dilution of 1:20). Plates were placed back in the 
incubator and the red-ox reaction, indicated by color change, was allowed to occur for 
4.5 - 6 h. Fluorescence at 595nm was detected using a Wallac Victor2, TM 1420 multilabel 
counter (PerkinElmer, Woodbridge, ON, Canada). An average background absorbance 
value, from medium-only wells, was subtracted from all experimental wells. Data are 
expressed as a percentage of C2 siRNA without drug. 
2.6. Measurement of TS, TK1 and TK2 mRNA levels 
2.6.1. RNA isolation and reverse transcription 
Cells were lysed for mRNA analysis using TRIzol Reagent (Invitrogen, CA, USA) and total 
cellular RNA was isolated according to the manufacturer’s protocol. RNA was quantified 
using UV-spectrometry. 
Purified RNA (1 μg) was used to synthesize cDNA by reverse transcription mediated by 
Moloney murine leukemia virus reverse transcriptase (MMLV-RT, Invitrogen) and 
random primers according to the protocol provided by the manufacturer. Samples were 
incubated at 25oC for 10 mins (annealing of primers), 37oC for 1 h (synthesis of cDNA by 
MMLV-RT), and 95oC for 5 mins (inactivation of MMLV-RT and separation of cDNA from 
RNA) using an Eppendorf Mastercycler Gradient thermal cycler (Eppendorf, Westbury, 
NY).  
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2.6.2. Quantitative PCR (qPCR) 
qPCR was used to determine the relative levels of TS, TK1, TK2 mRNA compared to 
either 18S rRNA or GAPDH mRNA levels (housekeeping genes/internal standard) using a 
TaqMan Gene Expression Assay kit (Applied Biosystems, USA) and specific, to gene of 
interest (GOI), primers and probes sets (Table 5). Standard curves were prepared using 
the cDNA of the sample with the highest expected level of target mRNA. Standard 
curves were composed of serial dilutions of cDNA and a no template control of RNase-
free water. The 1X standard curve initial sample contained 2.5 times the amount of 
cDNA of experimental sample; experimental samples contained 1 μL of cDNA in RNase-
free water. A general primer and probe master mix contained: 2X TaqMan® Universal 
PCR Master Mix (PE Applied Biosystems, Streetsville, ON), and either i) GAPDH or r18S 
Pre-Developed TaqMan® assay (Applied Biosystems), or ii) 100 μM of GOI Forward 
Primer, 100 μM GOI Reverse Primer, and 100 μM GOI fluorescently labeled probe. 
qPCR amplification was performed using either the ABI Prism® 7900HT Detection 
System (Applied Biosystems), for Chapter 3, or the ViiA 7 TM Real-time PCR System 
(Applied Biosystems, Life Technologies Holdings, Singapore), for Chapter 4, using the 
default standard instrument run properties: 50 oC for 2 mins and then 95oC for 10 mins 
(incubation steps), followed by 40 cycles of 95oC for 10 seconds (denature), and 60 oC 
for 1 min (annealing of primers and DNA polymerization).  
In Chapter 3 results, TS was multiplexed with the r18S housekeeping gene; r18S is used 
as the internal control throughout the chapter. In Chapter 4, TK2 was multiplexed with 
the GAPDH housekeeping gene; GAPDH is used as the internal control throughout the 
chapter. Multiplexing allows for assaying of multiple genes in a single well by using 
gene-specific probes with different, non-overlapping emission spectra, fluorescent tags. 
TS, TK1 or TK2 mRNA levels were normalized to the internal standard (r18S or GAPDH) 
and expressed as a percentage of the experimental control condition (C2 siRNA, unless 
otherwise indicated).   
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Table 5: Primers and probes for mRNA detection and quantification by qPCR.  
FAM, NED, and VIC are laser-activated fluorescent probes. MGB/NFQ refers to the specific 
quencher present in the probe. 
 
Gene of 
Interest 
Forward Primer Reverse Primer TaqMan Probe 
TS 5’-GGCCTCGG 
TGTGCCTTT-3’ 
5’-GATGTGCGCA 
ATCATGTACGT-3’ 
6FAM-AACATCGCCAG 
CTACGCCCTGC-MGB/NFQ 
TK1 5’-TTCCTACCTCT 
GGTGATGGTTTC-3’ 
5’-TGCCACCCAT 
CTTGGTGAA-3’ 
NED-ACAGGAACAA 
CAGCATC-MGB/NFQ 
TK2 5’-CTGGCGAAG 
GCAGAACCTT-3’ 
5’-TTCTCAAAGAC 
AGACCCCACATG-3’ 
6FAM-CTACCAGG 
AATCTTG-MGB/NFQ 
r18S As supplied As supplied VIC-labelled - as supplied 
GAPDH As supplied As supplied VIC-labelled - as supplied 
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2.7. Measurement of TS, TK1, TK2 and dCK protein levels 
2.7.1. Isolation and quantification of total protein  
Total cell protein lysates were obtained at indicated times as follows. Flasks or wells 
were placed on ice, cells were washed twice with 4oC -cold PBS, scraped and re-
suspended into cell lysis buffer (10 mM Tris at pH 7.6, 0.1% SDS, 1% Triton X-100,  2 mM 
EDTA), and sonicated at 4oC using a Vibra CellTM ultrasonic processor (Sonics & Materials 
Inc., Danbury, CT) to disrupt membranes.  
Protein concentration was estimated using a Bio-Rad Protein Assay kit (Bio-Rad, QC, 
Canada) following the protocol provided by the manufacturer. The required amount of 
total protein (Table 6) was then combined with water and loading buffer (supplemented 
with 2’-β-mercaptoethanol) and heated to 95oC for 5 mins (denaturing).  
2.7.2. Gel electrophoresis and immunoblotting  
Proteins were separated using SDS-polyacrylamide gel electrophoresis and transferred 
to a nitrocellulose membrane (Hybond-ECL, GE Healthcare-Amersham Biosciences, UK). 
See Table 6 for pertinent antibody information, total protein loaded amounts and 
percentages of acrylamide in gels. Membranes were blocked for 1 hour (5% milk in TBS-
T: TBS plus Tween 20 [0.2%]) and then washed with fresh TBS-T. Bands were detected as 
described in methods sections below. 
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Table 6: Description of antibodies, gel and blotting conditions 
  
Protein of 
Interest 
Protein Size 
(and band 
size if 
different) 
Total 
Protein 
Loaded 
% of 
Acrylamide 
in Gel 
Antibody Used & 
Dilution 
Chapter 
used in 
Thymidylate 
Synthase (TS) 
~ 35 kDa 25 μg 12 % Anti-TS antibody 
(Taiho 
Pharmaceuticals, 
Hanno-City, Japan) 
1:800 
Chapter 3 
Thymidine 
Kinase 1 (TK1) 
~25 kDa 40 μg 12 % Anti-TK1 antibody 
(34003, QED 
Bioscience Inc., San 
Diego, CA, USA) 1:400 
Chapter 3 
Thymidine 
Kinase 2 (TK2) 
~35 kDa 40 μg 12 % Anti-TK2 antibody 
(SAB1300098, Sigma-
Aldrich, Saint Louis, 
MO, USA) 1:150 
Chapter 3 
Thymidine 
Kinase 2 (TK2) 
(~35 kDa 
and at times 
31 kDa ) 
more 
reliable 
antibody 
35 μg 15 % Anti-TK2 antibody 
(HPA041162, Sigma-
Aldrich) 
1:12000 
Chapter 4 
Deoxycytidine 
Kinase (dCK) 
~31 kDa 
(28 kDa) 
35 μg 15 % Anti-dCK antibody 
(ab83046, Abcam, 
1:400 in 5% BSA) 
Chapter 4 
Actin ~42 kDa Depends on 
above 
loaded 
amounts - 
internal 
standard 
12-15 % Anti- actin antibody 
(α-actin, Sigma-
Aldrich) 1:1000 
Chapter 3 
and 4 
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2.7.2.1. Immunoblotting in Chapter 3 
2.7.2.1.1. TS and Actin immunoblots 
Membranes were probed with rabbit polyclonal anti-human TS primary antibody (1:800 
in TBS-T with 1% skim milk, 1 h, 20o C), followed by rabbit polyclonal anti-human Actin 
primary antibody (1:1000 in TBS-T with 1% skim milk, 1 h, 20oC), followed by 
horseradish peroxidase-conjugated anti-rabbit IgG secondary antibody (GE Healthcare-
Amersham Biosciences, UK, 1:3,000 in TBS-T with 1% skim milk, 1 h, 20oC) in preparation 
for TS and Actin band detection. Washing with TBS-T occurred after each probe. 
2.7.2.1.2. TK1, TK2 and Actin immunoblots 
Membranes were probed with rabbit polyclonal anti-human TK2 primary antibody 
(1:150 in TBS-T with 1% skim milk, 16 h, 4oC) followed by horseradish peroxidase-
conjugated α-rabbit IgG secondary antibody (1:3000 in TBS-T with 1% skim milk, 1 h, 
20oC) in preparation for TK2 band detection. Washing with TBS-T occurred after each 
probe. Bands were detected and quantified as described in methods section 2.7.3. 
Immunoblot band detection and quantification. Membranes were then stripped using 
Restore Western Blot Stripping Buffer (Thermo Scientific, Rockford, IL, USA ,15 minutes, 
20oC), washed with TBS-T, blocked in TBS-T with 5% skim milk and cut into two pieces (≥ 
37 kDa and ≤ 37 kDa) using the Kaleidoscope Precision Plus Protein Standards Ladder 
(BioRad, Carlsbad, CA, USA) as a guide. 
Membranes containing proteins of a 37kD size or smaller were probed with mouse 
polyclonal anti-human TK1 primary antibody (1:400 in TBS-T with 1% skim milk, 1 h, 
20oC) followed by horseradish peroxidase-conjugated anti-mouse IgG secondary 
antibody (GE Healthcare-Amersham Biosciences, UK 1:3,000 in TBS-T with 1% skim milk, 
1 h, 20oC) in preparation for TK1 band detection. Washing with TBS-T occurred after 
each probe. 
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Membranes containing proteins of a 37 kDa size or greater were probed with rabbit 
polyclonal anti-human Actin primary antibody (1:1000 in TBS-T with 1% skim milk, 1 h, 
20oC) followed by horseradish peroxidase-conjugated anti-rabbit IgG secondary 
antibody (1:3,000 in TBS-T with 1% skim milk, 1 h, 20oC) in preparation for Actin band 
detection. Washing with TBS-T occurred after each probe. 
2.7.2.2. Immunoblotting in Chapter 4 
2.7.2.2.1. TK2 and Actin immunoblots 
After blocking, membranes were cut into two pieces (>37 kD and <37 kD) using the 
Kaleidoscope Precision Plus Protein Standards Ladder as a guide. 
Membranes containing proteins of a 37kD size or smaller were probed with rabbit 
polyclonal anti-human TK2 primary antibody (1:12,000 in TBS-T with 1% skim milk, 1h, 
20oC) followed by horseradish peroxidase-conjugated α-rabbit IgG secondary antibody 
(1:8000 in TBS-T with 1% skim milk, 1 h, 20oC) in preparation for TK2 band detection. 
Washing with TBS-T occurred after each probe. 
Membranes containing proteins of a 37 kDa size or greater were probed with rabbit 
polyclonal anti-human Actin primary antibody (1:1000 in TBS-T with 1% skim milk, 1 h, 
20oC) followed by horseradish peroxidase-conjugated anti-rabbit IgG secondary 
antibody (1:8,000 in TBS-T with 1% skim milk, 1 h, 20oC) in preparation for Actin band 
detection. Washing with TBS-T occurred after each probe. 
2.7.2.2.2. dCK and Actin immunoblots 
After blocking, membranes were cut into two pieces (>37 kD and <37 kD) using the 
Kaleidoscope Precision Plus Protein Standards Ladder as a guide. 
Membranes containing proteins of a 37kD size or smaller were probed with rabbit anti-
human dCK primary antibody (1:400 in TBS-T with 5% BSA, 36 h, 4oC) followed by 
horseradish peroxidase-conjugated α-rabbit IgG secondary antibody (1:10,000 in TBS-T 
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with 1% skim milk, 1 h, 20oC) in preparation for dCK band detection. Washing with TBS-T 
occurred after each probe. 
Membranes containing proteins of a 37 kDa size or greater were probed with rabbit 
polyclonal anti-human Actin primary antibody (1:1000 in TBS-T with 1% skim milk, 1 h, 
20oC) followed by horseradish peroxidase-conjugated anti-rabbit IgG secondary 
antibody (1:8,000 in TBS-T with 1% skim milk, 1 h, 20oC) in preparation for Actin band 
detection. Washing with TBS-T occurred after each probe. 
2.7.3. Immunoblot band detection and quantification 
Horseradish peroxidase activity associated with protein bands was detected using 
Enhanced Chemiluminescence Plus (ECL Plus; GE Healthcare-Amersham Biosciences, UK 
- Chapter 3) or Pierce® ECL 2 Western Blotting Substrate (Thermo Scientific, Rockford, IL 
- Chapter 4) and a STORM 860 Molecular Imager (phosphoimager/fluoroimager) 
(Amersham Biotech-Molecular Dynamics Inc, CA, USA). Band intensity was quantified 
using ImageQuant 5.1 software (Amersham Biotech-Molecular Dynamics Inc., 
Sunnyvale, CA, USA). TS, TK1, TK2, and dCK results are expressed normalized to the 
Actin internal standard and then as a percentage of an experimental control condition 
(C2 siRNA unless otherwise indicated). 
2.8. Measurement of mitochondrial DNA (mtDNA) and nuclear DNA 
(nDNA) 
The methods for this section, targets chosen, and primer and probe sequences used 
were based on published literature [266-270]. The ratio of mitochondrial DNA (mtDNA) 
to nuclear DNA (nDNA) allows determination of the effect of experimental treatments 
on mtDNA. It also serves as an indirect representation of the effect of treatment on 
mitochondrial health, function and biogenesis and allows determination of whether 
treatments preferentially affect mitochondrial DNA as compared to nuclear DNA. 
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2.8.1. DNA isolation  
Cells were washed twice with cold PBS, trypsinized, collected in medium containing 10% 
FBS, centrifuged at 218 rcf for 10 mins, washed with cold PBS, and centrifuged again. 
Total DNA was isolated from cell pellet using a phenol-ethanol extraction protocol with 
Digestion Buffer (100 mM NaCl + 50 nM Tris HCl pH 8.0 + 50 mM EDTA) supplemented 
with Proteinase K (200 μg/mL) and an additional ethanol precipitation step to further 
purify the DNA. DNA was quantified using UV-spectrometry. 
2.8.2. Quantitative PCR (qPCR) for mtDNA:nDNA ratio 
mtDNA and nDNA reactions were not multiplexed. Reactions were amplified using 
TaqMan-based primer-probe sets specific to a mtDNA or nDNA target GOI (Table 7).  
Standard curves were prepared using DNA from the sample with the highest expected 
amount of target. The curve was composed of 1:10 serial dilutions of DNA and a no 
template control of RNase free water. The 1X standard curve initial sample contained 
4000 ng of DNA. Each experimental sample contained 300 ng of DNA. A general primer 
and probe master mix contained: 2X TaqMan® Universal PCR Master Mix (PE Applied 
Biosystems), 100 μM of GOI Forward Primer, 100 μM GOI Reverse Primer, and 100 μM 
GOI fluorescently labeled probe. 
qPCR amplification was performed using the ViiA 7 TM Real-time PCR System (Applied 
Biosystems) and the default standard instrument run properties: 50 oC for 2 mins and 
then 95oC for 10 mins (incubation steps), followed by 40 cycles of 95oC for 10 seconds 
(denature), and 60 oC for 1 min (annealing of primers and DNA polymerization). mtDNA 
levels were normalized to r18S and then expressed as a percentage of the experimental 
control condition (C2 siRNA).     
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Table 7: Primers and probes used for qPCR to produce mtDNA:nDNA ratio 
 
Gene of 
Interest 
Forward Primer Reverse Primer TaqMan Probe 
NADHD1 
(mtDNA) 
5’-CACCCAAGA 
ACAGGGTTTGT-3’ 
5’-TGGCCATGG 
GTATGTTAA-3’ 
6FAM-5’-TTACCGTCT 
GCCATCT-3’-MGBNFQ 
r18S 
(nDNA) 
5’-TAGAGGGAC 
AAGTGGCGTTC-3’ 
5’-CGCTGAGCC 
AGTCAGTGT-3’ 
VIC-5’-AGCAATAGG 
TCTGTGATG-3’-MGBNFQ 
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2.9 Flow cytometry 
Cells were washed with 4oC cold PBS, trypsinized, re-suspended in 4oC cold medium 
containing 10% FBS, pelleted by centrifugation, washed and re-suspended in 4oC cold 
PBS, and pelleted again by centrifugation at 218 rcf for 10 mins. 
2.9.1 Determination transfection efficiency using Cy3-labelled siRNA 
In keeping with our experimental protocol of when additional medium or re-plating 
occurs, 4 h after transfection cells were re-suspended in 400 uL of PBS and run using the 
FLH-2 channel of a BD FACSCalibre flow cytometer (Becton Dickson Immunocytometry 
Systems, San Jose, CA) without fixation. The number of events collected per sample run 
was set to 10,000. 
2.9.2. Determination of mitochondrial activity using MitoTracker® Red CMXRos 
Cells were processed as per manufacturer’s protocol. Briefly, cell pellets were re-
suspended in a 200nM final concentration of MitoTracker® Red CMXRos (Invitrogen, 
Eugene, OR) in 37oC PBS and incubated in the dark at 37oC for 20 minutes. Cells were 
then washed with PBS and pelleted twice by centrifugation at 218 rcf for 10 mins. Cell 
pellets were resuspended in 400 uL of PBS and run using the FLH-2 channel of a BD 
FACSCalibre flow cytometer (Becton Dickson Immunocytometry Systems) without 
fixation. A sample containing the same cell lines as experimental samples, but without 
exposure to MitoTracker® was also run as a non-stained control. The number of events 
collected per sample run was set to 12, 000. 
2.9.3. Analysis of flow cytometry results 
Analysis of flow cytometry results was carried out using FlowJo V10 software (Tree Star 
Inc., Ashland, OR). Forward scatter and side scatter of control, non-labeled cells were 
used to placed a “live cell” gate upon the experimental samples. A histogram for each 
sample was then generated for FLH-2 detection events (representing either Cy3-labelled 
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siRNA or MitoTracker®). Mean fluorescent intensity (MFI) was calculated. MFI refers to 
the average fluorescence intensity of each event and is a representation of abundance 
in expression, activity, etc, depending on the fluorescent probe. Results are expressed 
as a percentage of control treatment MFI.   
2.10. Statistical analysis of results 
In most experiments, three independent replicate experiments were performed (n=3 in 
each experiment). For each experiment, the mean was calculated. The average of 3 
means ± SEM was calculated (i.e. a “mean of means” ± standard error of the “mean of 
means”) and is presented in the results sections. Thus, the “mean of means” reflects an 
n of 9 and includes both intra- and inter-experimental error. Unless otherwise indicated 
in figure legends, the “mean of means” analysis applies in all cases.  
ANOVA was used to determine significant differences among normally distributed 
means. Student’s t tests were used to determine significant differences between 
normally distributed means. The level of significance for all statistical analyses was 
chosen a priori to be p < 0.05. 
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Chapter 3  
« Results Part 1: Combining siRNAs targeting TS, TK1 or TK2 sensitizes 
human tumour cells to 5FUdR and pemetrexed » 
The majority of results presented in this chapter were previously published in 2011 in 
The Journal of Pharmacology and Experimental Therapeutics [264] and have been 
reprinted with permission of the American Society for Pharmacology and Experimental 
Therapeutics (all rights reserved) (see Appendix 2). The text and figures have been 
modified to conform to the monograph style. Unpublished data are discussed and 
pertain to Figures 15-19.  
Currently, there are no small molecule drugs commercially available to target human 
TK1 or TK2. Thus, antisense molecules were used to decrease the activity of these 
enzymes. TK1 siRNA and TK2 siRNA were used alone and in combination with TS siRNA 
and/or TS-targeting drugs to assess whether TK plays a role in mediating resistance to 
TS-targeting interventions. Cell lines were treated with low siRNA concentrations that 
maximized knockdown of target mRNAs, minimized non-specific effects, and yielded 
consistent target downregulation in replicate experiments. Unless otherwise stated, TS, 
TK1, and TK2 targeting siRNAs were each used at 5 nM. Total siRNA concentrations were 
held constant at 10 nM by adding non-targeting C2 siRNA to siRNAs targeting TS, TK1, or 
TK2 where necessary, a maneuver that did not alter the effectiveness of siRNAs 
(Appendix 1). 
3.1. Abstract 
Thymidylate synthase (TS) is the only de novo source of thymidylate (dTMP) for DNA 
synthesis and repair. Drugs targeting TS protein are a mainstay in cancer treatment, but 
off-target effects and toxicity limit their use. Cytosolic thymidine kinase (TK1) and 
mitochondrial thymidine kinase (TK2) contribute to an alternative dTMP-producing 
pathway, by salvaging thymidine from the tumour milieu, and may modulate resistance 
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to TS-targeting drugs. Combined downregulation of these enzymes is an attractive 
strategy to enhance cancer therapy. We have previously shown that antisense targeting 
TS enhanced tumour cell sensitivity to TS-targeting drugs in vitro and in vivo. As both TS 
and TKs contribute to increased cellular dTMP, we hypothesized that TKs mediate 
resistance to the capacity of TS siRNA to sensitize tumour cells to TS-targeting 
anticancer drugs. We assessed the effects of targeting TK1 or TK2 with siRNA alone and 
in combination with siRNA targeting TS and/or TS-protein targeting drugs on tumour cell 
proliferation. Downregulation of TK with siRNA enhanced the capacity of TS siRNA to 
sensitize tumour cells to traditional TS protein-targeting drugs (5FUdR and pemetrexed). 
The sensitization was greater than that observed in response to any siRNA used alone, 
and was specific to drugs targeting TS. Upregulation of TK1 in response to combined 
5FUdR and TS siRNA suggests that TK knockdown may be therapeutically useful in 
combination with these agents. TKs may be useful targets for cancer therapy when 
combined with molecules targeting TS mRNA and TS protein. 
3.2. siRNAs downregulate respective target mRNAs  
3.2.1. TS and TK siRNAs decrease target mRNAs in HeLa and MCF7 cells 
Two different siRNAs targeting TS [TS siRNA(1) and TS siRNA(2)] were evaluated. TS 
siRNA(1) and TS siRNA(2) each downregulated TS mRNA by 70-85% in HeLa (Figure 3A) 
and MCF7 (Figure 4A) cells. The capacity of either TS siRNA to downregulate TS was 
unaffected by simultaneously targeting TK1 or TK2 using one of two different TK siRNAs 
(in combination with TS siRNA), in both HeLa (Figure 3A) and MCF7 (Figure 4A) cells.  
Similarly, two different siRNAs targeting TK1 [TK1 siRNA(1) and TK1 siRNA(2)] 
downregulated TK1 mRNA by 60-80% in HeLa (Figure 3B) and MCF7 (Figure 4B) cells. In 
MCF7 (but not HeLa) cells, TK1 siRNA(1) downregulated TK1 more effectively than TK1 
siRNA(2). The capacity of either of the two TK1 siRNAs to downregulate TK1 was 
unaffected by simultaneous administration of TS siRNA in HeLa cells (Figure 3B) and 
MCF7 (Figure 4B) cells.  
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TK2 mRNA was also downregulated by siRNAs, although to a more variable and lesser 
degree than TS and TK1. Two different siRNAs [TK2 siRNA(1) and TK2 siRNA(2)] 
downregulated TK2 by more than 80% in HeLa cells (Figure 3C) and 45-50% in MCF7 
cells (Figure 4C), and combined treatment with TS siRNAs did not alter their 
effectiveness. TK2 siRNA(1) was a more effective siRNA than TK2 siRNA(2) in both HeLa 
(Figure 3C) and MCF7 cells (Figure 4C).  
These experiments tested 2 different siRNAs for each target mRNA (TS, TK1, and TK2) in 
HeLa and MCF7 cell lines. Results were obtained 24 h post-transfection. TS siRNA(2), TK1 
siRNA(1), and TK2 siRNA(1) were the most effective among the 6 siRNAs tested and 
were selected for use in subsequent experiments. They are referred to as TS siRNA, TK1 
siRNA and TK2 siRNA, without distinguishing (1) or (2) for the remaining figures and 
results in this chapter. 
 
  
Figure 3: siRNAs targeting TS, TK1, and TK2 reduce target mRNA in HeLa cells at 24 h 
post-transfection.  
HeLa cells were treated with various combinations of 5 nM TS, TK1, and/or TK2 siRNA or control 
siRNAs (C2, C3; 10 nM total siRNA for 
TK1 mRNA levels are shown in 
transfection. Two different siRNAs were used against target mRNA. Changes in target mRNA 
levels were calculated as a percent of mRNA levels in cells transfected with control (C2) siRNA. 
*different from cells treated with control (C2) siRNA (p<0.05, Student’s 
cells treated with siRNA targeting a different sequence in the same mRNA (
 
each treatment). TS mRNA levels are shown in 
panel B, and TK2 mRNA levels are shown in panel C
t test). 
p <0.05, ANOVA).
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panel A, 
 at 24 h post 
a different from 
 
  
Figure 4: siRNAs targeting TS, TK1, and TK2 reduce target mRNA in MCF7 cells at 24 h 
post-transfection.  
MCF7 cells were treated with various combinations of 5 nM TS, TK1, and/or TK2 siRNA or control 
siRNAs (C2, C3; 10 nM total siRNA for each treatment). TS mRNA levels are shown in 
TK1 mRNA levels are shown in 
transfection. Two different siRNAs were used against target mRNA. Changes in target mRNA 
levels were calculated as a percent of mRNA levels in cells transfected with control (C2) siRNA. 
*different from cells treated with control (C2) siRNA (p<0.05, Student’s 
cells treated with siRNA targeting a different sequence in the same mRNA (p<0.05, ANOVA). 
panel B, and TK2 mRNA levels are shown in panel C
t test). 
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3.2. Effects of targeting TS and/or TK1 or TK2 with siRNA in 
combination with the cytotoxic drug 5FUdR 
3.2.1. Combined treatment with TS and TK2 siRNA sensitized HeLa cells to 5FUdR 
better than TS siRNA alone 
To assess the outcome of combined reduction of both TS and TKs to enhance the 
activity of a TS-targeting drug, the effect of siRNA downregulation on HeLa cell 
proliferation was measured using: (i) TS or TK siRNAs alone; (ii) in combination, and (iii) 
followed by a period of treatment with or without 5FUdR. Results were obtained 96 h 
post-transfection and treatment with drug. 
As single agents, siRNAs targeting TS, TK1, and TK2 had no effect on HeLa cell 
proliferation compared to treatment with control, non-targeting siRNA (Figure 5 A). As 
expected, treatment with 5FUdR (IC50) without knockdown of TS, TK1, or TK2 inhibited 
proliferation by approximately 50%. Neither TK1 siRNA nor TK2 siRNA enhanced the 
anti-proliferative effect of 5FUdR (Figure 5A). siRNA knockdown of TS prior to 5FUdR 
treatment enhanced the anti-proliferative effect of 5FUdR by approximately by two-
fold(compared to C2 siRNA, Figure 5A) as reported previously [215, 216, 219, 271]. 
However, in the context of 5FUdR treatment, when cells were treated with both TS 
siRNA and TK2 siRNA, proliferation was further reduced by approximately 20% 
compared to treatment with TS siRNA alone (Figure 5B). This is an overall decrease of 
approximately 60% versus 50% when each was compared to C2 siRNA with drug (Figure 
5A). The capacity of TK knockdown to increase TS siRNA-mediated enhancement of the 
anti-proliferative effect of 5FUdR was specific to TK2 (Figure 5). siRNA knockdown of 
TK1 had no effect on TS siRNA enhancement of 5FUdR activity. 
  Figure 5: Simultaneous treatment with TS and TK2 siRNAs sensitizes HeLa cells to 
5FUdR better than treatment with TS siRNA alone. 
(A) HeLa cells were treated with control siRNA, TS siRNA, TK1 siRNA, and TK2 siRNA, in various 
combinations, followed by 5FUdR (IC
proliferation was measured by counting cells (as described in 
2.5.1. Cell counting). (B) Proliferation of cells treated with 5FUdR plus TS siRNA, with or without 
TK2 siRNA. Proliferation of cells untreated with drug or siRNAs, and cells treated with various 
siRNAs alone, were calculated as a percentage of the fold increase in number of cells treated 
with control (C2) siRNA only. Proliferation of cells treated with 5FUdR was c
percent of respective siRNA
that transfection conditions had minimal effects on proliferation. *different from cells treated 
with control (C2) siRNA and 5FUdR (p<0.05, ANOVA). 
siRNA(1) plus C2 siRNA and 5FUdR (
which 5FUdR is present, there is a statistically significant reduction in proliferation (
ANOVA). 
 
 
50) (black bars) or no drug(white bars) for 96 h and 
Methods Section 
alculated as a 
-treated cells fold-change without 5FUdR. NTC and LF2K data show 
adifferent from cells treated with TS 
p<0.05, ANOVA and/or Student’s t test). For all conditions in 
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2.4. siRNA  and 
p<0.05, 
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3.2.2. siRNA downregulation of TS, TK1 and TK2 persisted up to 96 h post-transfection 
with, and without, 5FUdR treatment 
TS siRNA, TK1 siRNA, and TK2 siRNA were applied to HeLa cells in four different 
treatment protocols: (1) as single agents, (2) TS siRNA combined with TK1 siRNA, (3) TS 
siRNA combined with TK2 siRNA, and (4) followed by treatment with 5FUdR. All siRNAs 
downregulated their target mRNA, and protein, regardless of regimen, up to 96 h post-
transfection (Figure 6 for TS levels, Figure 7 for TK1 levels, and Figure 8 for TK2 levels). 
The degree of mRNA downregulation at 96 h was less than that at 24 h post-transfection 
(Figure 3). At 96 hours after treatment with TS siRNA alone, TS mRNA levels were 28% of 
control (Figure 6A) compared to 7% of control at 24 h (Figure 3A). At 96 h after TK1 
siRNA treatment alone, TK1 mRNA was 52% of control (Figure 7A) compared to 10% of 
control at 24 hours (Figure 3B). At 96 h after TK2 siRNA treatment alone, TK2 mRNA was 
75% of control (Figure 8A) compared to 16% of control at 24 h (Figure 3C). Similarly, 
time-dependent attenuation of target mRNA was evident under conditions where TS 
siRNA was combined with TK1 siRNA or TK2 siRNA, with or without 5FUdR (i.e., the 
degree of mRNA downregulation was greater at 24 h than at 96 h).  
All siRNAs decreased target protein levels at 96 h post-transfection. TS siRNA alone, or 
in combination with TK1 siRNA or TK2 siRNA, decreased TS protein by 70% (Figure 6B). A 
similar level of TS mRNA and protein downregulation was observed in the presence of 
5FUdR (Figure 6A & C). 5FUdR did not affect the capacity of TS siRNA to downregulate 
TS mRNA and protein. TK1 siRNA alone, or in combination with TS siRNA, reduced TK1 
protein by 57% (Figure 7B) and the capacity of TK1 siRNA to downregulate TK1 mRNA 
and protein was unaffected by 5FUdR (Figure 7A & C). TK2 siRNA alone, or in 
combination with TS siRNA, reduced TK2 protein by 30% (Figure 8B). 5FUdR did not 
affect the ability of TK2 siRNA to downregulate TK2 mRNA and protein (Figure 8A & C) 
compared to conditions without 5FUdR.  
 
 Figure 6: TS siRNA reduces both TS mRNA 
simultaneous administration of TK siRNAs and/or 5FUdR. 
HeLa cells were treated with control and/or targeting siRNAs in various combinations, followed 
by media alone or media plus 5FUdR, and specific mRNA and prot
later (as described in Methods and Methods Sections Section 
TK2 mRNA levels and  
 
2.7.2.1. Immunoblotting in 
siRNA without 5FUdR). (B & C)
5FUdR) without (B) and with 
per lane) are shown (Ld, molecular weight ladder; lane 1, untreated control; lane 2, LFA2K; lane 
3, C2; lane 4, C3; lane 5, TS + C2; 
+TK2). Double TS protein bands 
TS. *,Different from cells treated with control (C2) siRNA (p
test). a, Different from cells treated identically but without 5FUdR (p
and protein in HeLa cells, with or without 
 
ein levels were measured 96 h 
2.6. Measurement of TS, TK1 and 
Chapter 3). (A) Relative TS mRNA (expressed as a percent of C2 
 Relative TS protein (expressed as a percent of C2 siRNA without 
(C) 5FUdR. Representative immunoblots (one treatment condition 
lane 6, TK1 + C2; lane 7, TK2 + C2; lane 8, TS +TK1; lane 9, TS 
(C) are due to the presence of both unbound and 5FUdR
≤0.05, ANOVA and/or Student’s 
≤0.05, Student’s 
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-bound 
t 
t test).  
 Figure 7: TK1 siRNA reduces both TK1 mRNA and protein in HeLa cells, with or without 
simultaneous administration of TS siRNAs and/or 5FUdR.
HeLa cells were treated as described in the legend to 
(expressed as a percent of C2 siRNA without 5FUdR). 
a percent of C2 siRNA without 5FUdR) without 
immunoblots (one treatment condition per lane) are shown (Ld, molecular weight ladder; lane 
1, untreated control; lane 2, LFA2K; lane 3, C2; 
7, TK2 + C2; lane 8, TS +TK1; lane 9, TS +TK2). *Different from cells treated with control (C2) 
siRNA (p<0.05, ANOVA and/or Student’s 
without 5FUdR (p<0.05, Student’s 
 
 
Figure 6. (A) Relative TK1 mRNA 
(B & C) Relative TK1 protein (expressed as 
(B) and with (C) 5FUdR. Representative 
lane 4, C3; lane 5, TS + C2; lane 6, TK1 + C2; lane 
t test). a, Different from cells treated identically but 
t test). 
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 Figure 8: TK2 siRNA reduces both TK2 mRNA and protein in HeLa cells, with or without 
simultaneous administration of TS siRNAs and/or 5FUdR.
HeLa cells were treated as described in the legend to
of that in cells treated with C2 siRNA). 
treated with C2 siRNA) without 
treatment condition per lane) are shown (Ld, molecular weight ladder; lane 1, untreated 
control; lane 2, LFA2K; lane 3, C
lane 8, TS +TK1; lane 9, TS +TK2). Bars represent means ± SE (panel B: n=6 independent 
experiments, panel C: n= 3 independent experiments, triplicates per treatment group). 
*Different from cells treated with control (C2) siRNA (p<0.05, ANOVA and/or Student’s 
 
 Figure 6. (A) Relative TK2 mRNA (percent 
(B & C) Relative TK2 protein (percent of that in cells 
(B) and with (C) 5FUdR. Representative immunoblots (one 
2; lane 4, C3; lane 5, TS + C2; lane 6, TK1 + C2; lane 7, TK2 + C2; 
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t test).  
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3.2.3. TK1 protein increased as a result of combined TS siRNA and 5FUdR treatment  
In the context of treatment with 5FUdR, cells treated with TS siRNA had a twofold 
increase in TK1 protein levels (Figure 7C) compared to the level seen after treatment 
with TS siRNA without 5FUdR (Figure 7B). Similar results are observed for combined 
treatment with TS and TK2 siRNA. The increase was not due to increased TK1 mRNA 
(Figure 7A) and was abolished when TK1 siRNA was combined with TS siRNA prior to 
5FUdR treatment (Figure 7C). A similar increase in TK2 protein levels was not seen when 
using TS siRNA, alone or in combination with TK1, and/or 5FUdR (Figure 8B & C).  
3.3. Effects of targeting TS and/or TK1 or TK2 with siRNA in 
combination with pemetrexed 
3.3.1. Combined treatment with TS and TK1 siRNAs sensitized HeLa cells to the 
cytotoxic drug pemetrexed better than TS siRNA alone 
HeLa cells were treated with siRNAs and pemetrexed (at the IC50 concentration) and the 
effects on proliferation were evaluated 96 h later. TS siRNA alone, or combined with TK1 
or TK2 siRNAs, had no effect on cellular proliferation, without pemetrexed present, 
when compared to treatment with C2 siRNA (Figure 9A). Compared to C2 siRNA, 
treatment with TS siRNA increased sensitivity to pemetrexed by more than 30% (Figure 
9A). Combined treatment with TK1 siRNA and TS siRNA enhanced pemetrexed-induced 
inhibition of proliferation by 25% more than that of pemetrexed plus TS siRNA alone 
(Figure 9 A & B). Overall, TS siRNA plus TK1 siRNA enhanced the antiproliferative effect 
of pemetrexed by approximately two-fold compared to C2 siRNA with pemetrexed 
(Figure 9A). The capacity of TK knockdown to increase TS siRNA-mediated enhancement 
of the antiproliferative effect of pemetrexed was specific to TK1. siRNA knockdown of 
TK2 had no effect on TS siRNA enhancement of pemetrexed activity (Figure 9 A & B). 
  
Figure 9: Simultaneous treatment with TS and TK1 siRNAs sensitizes HeLa
pemetrexed treatment better than TS siRNA alone.
(A) HeLa cells were treated with control siRNA, TS siRNA, TK1 siRNA, and TK2 siRNA, in various 
combinations, followed by pemetrexed (IC
Proliferation was measured as described in 
Proliferation of cells treated with pemetrexed plus TS
Proliferation results in panels A and B are expressed in the same format as those of 
*different from cells treated with control (C2) siRNA and pemetrexed (p<0.05, ANOVA). 
Different from cells treated with TS siRNA plus C2 siRNA and pemetrexed (
and/or Student’s t test). For all conditions in which pemetrexed is present, there is a statistically 
significant reduction in proliferation (
 
50) (black bars) or no drug (white bars
Methods Section 2.5.1. Cell counting
 siRNA, with or without TK1 siRNA. 
p<0.05, ANOVA 
p<0.05, ANOVA). 
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 cells to 
) for 96 h. 
. (B) 
Figure 5. 
a, 
63 
 
3.3.2. siRNA downregulation of TS, TK1, or TK2 persists up to 96 hours post-
transfection, with and without pemetrexed treatment  
As seen after combined treatment with siRNAs targeting TS or TS plus TK1 or TK2, with 
or without subsequent 5FUdR (Figure 6, Figure 7, Figure 8), siRNA-mediated 
downregulation of mRNA and protein targets was maintained up to 96 h post-
transfection of HeLa cells in the absence and presence of pemetrexed (TS, Figure 10; 
TK1, Figure 11; TK2, Figure 12). Control data, presented throughout the figures in this 
chapter, were generated from similar experiments, shown in each case because they 
were performed simultaneously with, and controlled for, potential variation in inter-
experiment culture conditions and cell characteristics. Data shown in Figure 8 B and 
Figure 12 B are identical and are shown in both figures to facilitate comparison with 
novel data. 
The addition of pemetrexed to TS siRNA increased TK2 protein to a level 70% higher 
than that observed after treatment with TS siRNA alone (Figure 12 B and C). This effect 
was negated by the presence of TK2 siRNA. There was no concomitant increase in TK1 
protein (Figure 11 C).  
 Figure 10: TS siRNA reduces both TS mRNA and protein in HeLa cells, with or without 
simultaneous administration of TK1 or TK2 siRNA and/or pemetrexed.
HeLa cells were treated with control and/or targeting siRNAs in various combinat
by media alone or media plus pemetrexed, and specific mRNA and protein levels were 
measured 96 h later as described in 
that in cells treated with C2 siRNA). (B,C) Relative TS protein (p
with C2 siRNA) without (B) and with (C) pemetrexed. Representative immunoblots (one 
treatment condition per lane) are shown (Ld, molecular weight ladder; lane 1, untreated 
control; lane 2, LFA2K; lane 3, C2; lane 4, C3; lane
lane 8, TS +TK1; lane 9, TS +TK2). *
ANOVA and/or Student’s t test). 
(p<0.05, Student’s t test). 
 
 
 
Materials and Methods. (A) Relative TS mRNA (percent of 
ercent of that in cells treated 
 5, TS + C2; lane 6, TK1 + C2; lane 7, TK2 + C2; 
Different from cells treated with control (C2) siRNA (p<0.05, 
aDifferent from cells treated identically but without 5FUdR 
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ions, followed 
 Figure 11: TK1 siRNA reduces both TK1 mRNA and protein in HeLa cells, with or 
without simultaneous administration of TS siRNA and/or pemetrexed.
HeLa cells were treated as described in the legend to Figure 7. (
of that in cells treated with C2 siRNA). (
with C2 siRNA) without (B) and with (
treatment condition per lane) are shown (Ld
control; lane 2, LFA2K; lane 3, C2; lane 4, C3; lane 5, TS + C2; lane 6, TK1 + C2; lane 7, TK2 + C2; 
lane 8, TS +TK1; lane 9, TS +TK2).*Different from cells treated with control (C2) siRNA (p<0.05, 
ANOVA and/or Student’s t test). 
(p<0.05, Student’s t test). 
 
A) Relative TK1 mRNA (percent 
B,C) Relative TK1 protein (percent of that in cells treated 
C) pemetrexed. Representative immunoblots (one 
, molecular weight ladder; lane 1, untreated 
aDifferent from cells treated identically but without pemetrexed 
 
65 
 
 
 Figure 12: TK2 siRNA reduces both TK2 mRNA and protein in HeLa cells, with or 
without simultaneous administration 
HeLa cells were treated as described in the legend to Figure 7. (
of that in cells treated with C2 siRNA). (
with C2 siRNA) without (B) a
treatment condition per lane) are shown (Ld, molecular weight ladder; lane 1, untreated 
control; lane 2, LFA2K; lane 3, C2; lane 4, C3; lane 5, TS + C2; lane 6, TK1 + C2; lane 7, TK2 + C2; 
lane 8, TS +TK1; lane 9, TS +TK2). Bars represent means ± SE (
experiments, panel C: n= 3 independent experiments, triplicates per treatment group). 
*Different from cells treated with control (C2) siRNA (p<0.05, ANOVA and/or Student’s 
aDifferent from cells treated identically but without 5FUdR (p<0.05, Student’s 
 
of TS siRNA and/or pemetrexed.
A) Relative TK2 mRNA (percent 
B,C) Relative TK2 protein (percent of that in cells treated 
nd with (C) pemetrexed. Representative immunoblots (one 
panel B: n=6 independent 
t 
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t test). 
test). 
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3.4.The effect of TS siRNA and/or TK1 or TK2 siRNAs in combination 
with a non-TS-targeting drug 
3.4.1. siRNA-mediated reduction of TS and TKs does not enhance the cytotoxicity of 
cisplatin 
To investigate if the enhancement of sensitivity to drugs when using TS siRNA and a TK 
siRNA was specific to TS-targeting drugs, the previous methodology was used in 
combination with the non-TS-targeting drug cisplatin. TS and TK siRNAs, alone or in 
combination, had no effect on cisplatin-mediated inhibition of proliferation (Figure 13). 
Therefore, the enhancement of drug-mediated antiproliferative effects by siRNA 
knockdown of TS and TK in HeLa cells was specific to 5FUdR and pemetrexed. 
 
3.5. siRNAs do not effect proliferation 
To assess whether the siRNAs had an effect on cellular proliferation, the no-drug-
treatment conditions from Figure 5, Figure 9, and Figure 13 were compiled and 
statistical analysis was performed. Compared to the control siRNA, TS siRNA, TK1 siRNA, 
and TK2 siRNA used as single agents, or in various combinations, do not cause a 
reduction in HeLa cell proliferation (Figure 14). Compared to untreated cells, or cells 
treated with LF2K but without siRNA, the transfection of siRNAs, in general, into HeLa 
cells does cause a non-specific reduction in cellular proliferation (Figure 14). The 
reduction in proliferation is non-specific, as the decrease in proliferation is similar 
among both targeting and control, non-targeting siRNA sequences.  
 
 
 
 
 
  
 
 
 
Figure 13: HeLa cell sensitivity to cisplatin is not affected by TS and/or TK siRNAs.
HeLa cells were treated with control siRNA, TS siRNA, TK1 siRNA, and TK2 siRNA, in various 
combinations followed by cisplatin (IC
proliferation was measured as described in Methods Sections
counting. Proliferation of cells untreated with drug or siRNAs, and cells treated with various 
siRNAs alone, was calculated as a perce
Proliferation of cells treated with cisplatin was calculated as a percent of identically
without cisplatin. NTC and LF2K data are included to show that transfection conditions had 
minimal effects on proliferation. For all conditions in which cisplatin is present, there is a 
statistically significant reduction in proliferation (
 
 
 
 
 
 
50) (hatched bars) or no drug(white bars) for 96 h and 
 2.4. siRNA  and 2.5.1. Cell 
nt of cells treated with control (C2) siRNA only. 
p<0.05, ANOVA). 
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-treated cells 
  
Figure 14: Targeting siRNAs do not cause a reduction in HeLa 
HeLa cells were treated with control siRNA, TS siRNA, TK1 siRNA, and TK2 siRNA, in various 
combinations for 96 h and proliferation was measured as described in Methods Sections
siRNA  and 2.5.1. Cell counting
treated with various siRNAs alone, was calculated as a percent of cells treated with control (C2) 
siRNA. Bars represent means ± S.E.M. of n=9 independent experiments, with triplicates per 
treatment group for each experiment. *Different from NTC cell
ANOVA).  
 
 
 
 
 
 
proliferation.
. Proliferation of cells untreated with drug or siRNAs, and of
s and LF2K treated cells (p<0.05, 
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3.6.The effect of combined TS, TK1, and TK2 siRNAs used with TS-
targeting drugs: Using 3 different targeting siRNA sequences 
simultaneously 
3.6.1. Combined treatment with TS, TK1, and TK2 siRNAs does not cause further 
sensitization to 5FUdR compared to cells treated with TS  and TK2 siRNA 
To assess the effect of targeting all 3 dTMP-producing enzymes on inhibition of cellular 
proliferation by 5FUdR, HeLa cells were treated with TS siRNA [3 nM], TK1 siRNA [3 
nM]and TK2 siRNA [4 nM], or various combinations thereof, using C2 siRNA to top up 
siRNA concentrations to a total of 10 nM in all cases. Proliferation was measured by 
counting cells after 96 h. TS siRNA sensitized HeLa cells to the antiproliferative effects of 
5FUdR. Combined treatment with both TS and TK2 siRNAs further sensitized HeLa cells 
to 5FUdR beyond that seen with TS siRNA (Figure 15 and as previously shown in Figure 
5). The addition of TK1 siRNA to this combination did not cause further sensitization to 
5FUdR (Figure 15). In fact, the addition of TK1 siRNA to the combination of TS and TK2 
siRNAs negated the further sensitization to 5FUdR that was previously seen when 
compared to TS siRNA.    
3.6.2. Combined treatment with TS, TK1, and TK2 siRNAs does not cause further 
sensitization to pemetrexed compared to cells treated with TS  and TK1 siRNA 
HeLa cells were treated with the same siRNA concentrations used above (TS siRNA [3 
nM], TK1 siRNA [3 nM]and TK2 siRNA [4 nM]) and a similar experiment was carried out 
using pemetrexed as the TS-targeting drug. At 96 h post-transfection, TS siRNA resulted 
in an increased reduction in HeLa cell proliferation when cells also treated with 
pemetrexed (Figure 16). While treatment with TS and TK1 siRNAs resulted in increased 
sensitivity to pemetrexed, the addition of TK2 siRNA did not cause further sensitization 
to pemetrexed beyond that seen with TS siRNA (Figure 16 and as previously seen in 
Figure 9). Similar to results seen above with 5FUdR, the addition of TK2 siRNA to the 
combination of TS and TK1 siRNAs negated the further sensitization to pemetrexed that 
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was previously seen when compared to sensitization induced by treatment with TS 
siRNA alone.   
3.6.3. Total siRNA concentration used affects sensitization to TS-targeting drugs. 
Prior to the siRNA triple combination containing TS siRNA (3 nM), TK1 siRNA (3 nM), and 
TK2 siRNA (4 nM), triple combination experiments at a higher concentration of each 
targeting siRNA (4 nM) were attempted (i.e., the total siRNA concentration was 
increased to 15 nM). After transfection, cells were replated and exposed to drug-free 
medium, medium containing 5FUdR, or medium containing pemetrexed. For both 
5FUdR (Figure 17) and pemetrexed (Figure 18), increasing the total siRNA concentration 
to 15 nM negated the prior sensitization effects seen with either drug. At this total 
concentration of siRNA, HeLa cells did not experience a further sensitization to the anti-
proliferative effects of 5FUdR when TS siRNA (5 nM + 10 nM of C2 siRNA) was used or 
when TS and TK2siRNAs (5 nM of each + 5 nM of C2 siRNA) were used as previously seen 
in Figure 5, Figure 15 (using 10 nM siRNA), and in prior publications (using TS-targeting 
ODNs or siRNAs) from this laboratory [215, 219, 271]. Similarly, cells did not experience 
a further increase in sensitization to pemetrexed when TS and TK1 siRNAs were used or 
when only TS siRNA was used as previously seen in Figure 9, Figure 16, prior 
publications [215, 219, 271]. 
To assess if this phenomenon was specific to HeLa cells, similar experiments were 
carried out using Meso H28 cells, 5FUdR and either a 10 nM or 15 nM total 
concentration of siRNA (Figure 19). At the 10 nM total concentration of siRNA, in Meso 
H28 cells TS siRNA enhanced the inhibition of proliferation by FUdR by 35%. There was a 
further reduction in proliferation to 48% compared to C2 siRNA when TS siRNA was 
combined with TK2 siRNA, but not with TK1 siRNA (Figure 19 A). At the 10 nM total 
concentration of siRNA, Meso H28 cells show a 90% reduction in proliferation in all 
treatment conditions involving 5FUdR and TS siRNA (Figure 19 A). The effect of siRNAs 
and of 5FUdR in combination with siRNAs is decreased in the Meso H28 cell line when a 
total of 15 nM of siRNA is used compared to the 10 nM results. At the 15 nM total 
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concentration, TS siRNA alone did not cause a reduction in Meso H28 proliferation and 
combined effects with 5FUdR are decreased (Figure 19 B). This indicates that the 
decreased magnitude of the antiproliferative response which was based on an overall 
increase in the total concentration of siRNA used is not specific to HeLa cells.   
 
 
 
 
 
 
 
 
 
   
Figure 15: Combined treatment with TS siRNA, TK1 siRNA and TK2 siRNA does not 
cause further sensitization to 5FUdR compared to cells treated with TS and TK2
siRNAs.  
HeLa cells were treated with TS siRNA [3 nM], TK1 siRNA [3 nM] and TK2 siRNA [4 nM], or 
various combination thereof using C2 siRNA to top
when necessary. Cell were then treated with either medium alone or medium c
and cellular proliferation was then measured 96 h later as outlined in Methods Sections 
siRNA  and 2.5.1. Cell counting
(p<0.05, ANOVA). adifferent from cells treated with TS siRNA plus C2 siRNA and 5FUdR (
ANOVA and/or Student’s t test). For all conditions in which 5FUdR is present, there is a 
statistically significant reduction in proliferation (
 
  
 
 
 
-up to a 10 nM total concentration of siRNA 
. *different from cells treated with control (C2) siRNA and 5FUdR 
p<0.05, ANOVA). 
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ontaining 5FUdR 
2.4. 
p<0.05, 
  
Figure 16: Combined treatment with TS siRNA, TK1 siRNA 
cause further sensitization to pemetrexed co
siRNAs. 
HeLa cells were treated with TS siRNA [3 nM], TK1 siRNA [3 nM] and TK2 siRNA [4 nM], or 
various combination thereof using C2 siRNA to top
when necessary. Cell were then treated with either medium alone or medium containing 
pemetrexed and cellular proliferation was measured 96 h later as outlined in Methods Sections 
2.4. siRNA  and 2.5.1. Cell counting
pemetrexed (p<0.05, ANOVA). 
pemetrexed (p<0.05, ANOVA and/or Student’s 
present, there is a statistically significant reduction in
 
 
 
 
and TK2 siRNA does not 
mpared to cells treated with TS and TK1 
-up to a 10 nM total concentration of siRNA 
. *different from cells treated with control (
adifferent from cells treated with TS siRNA plus C2 siRNA and 
t test). For all conditions in which pemetrexed is 
 proliferation (p<0.05, ANOVA).
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C2) siRNA and 
 
  
Figure 17: At 15 nM total siRNA, siRNAs targeting TK2 siRNA and/or TS siRNA did not 
sensitize HeLa cells to 5FUdR. 
HeLa cells were treated with 5 nM each of TS siRNA, TK1 siRNA and TK2 siRNA, or various 
combination thereof using C2 siRNA to top
necessary. Cell were then treated with either medium alone or medium containin
cellular proliferation was measured 96 h later as outlined in Methods Sections 
2.5.1. Cell counting. For all conditions in which 5FUdR is present, there is a statistically significant 
reduction in proliferation (p
 
 
 
 
 
 
-up to a 15 nM total concentration of siRNA when 
<0.05, ANOVA). 
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g 5FUdR and 
2.4. siRNA  and 
  
 
Figure 18: At 15 nM total siRNA, targeting TS  and TK1 
pemetrexed.  
HeLa cells were treated with 5 nM each of TS siRNA, TK1 siRNA and TK2 siRNA, or various 
combination thereof using C2 siRNA to top
necessary. Cell were then treated with either medium alone or medium containing pemetrexed 
and cellular proliferation was measured 96 h later as outlined in Methods Sections 
and 2.5.1. Cell counting. For all conditions in which pemetrexed is present, there is a statistically 
significant reduction in proliferation (
 
 
 
 
 
 
 
 
siRNAs did not sensitize to 
-up to a 15 nM total concentration of si
p<0.05, ANOVA). 
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RNA when 
2.4. siRNA  
  
Figure 19: In Meso H28 cells, total siRNA concentration effects sensitivity to TS siRNA, 
TS siRNA plus TK2 siRNA and siRNAs in combination with 5FUdR. 
Meso H28 cells were treated with various concentrations of targeting siRNAs as previously 
described such that the total concentration of siRNA was held constant at either 10 nM, for 
or 15 nM for B) using C2 siRNA to top
medium alone or medium containing 5FUdR and cellular proliferation was measured 96 h later 
as outlined in Methods Sections 
5FUdR is present, there is a statistically significant reduction in proliferation (
#different from C2 siRNA with 5FUdR (
(p<0.05, ANOVA). *different from TS siRNA without 5FUdR (
 
 
-up when necessary. Cell were then treated with either 
2.4. siRNA  and 2.5.1. Cell counting. For all conditions in which 
p
p<0.05, ANOVA). #, different from C2 siRNA with 5FUdR 
p<0.05, ANOVA). 
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<0.05, ANOVA). 
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Chapter 4  
« Results Part 2: siRNA targeting of mitochondrial thymidine kinase 2 
(TK2) to sensitize cancer cells to gemcitabine » 
The results of this Chapter are currently being submitted for publication.  
The data presented here seeks to address if mitochondrial TK2 contributes to resistance, 
or decreased effectiveness of, gemcitabine chemotherapy. There exists a relationship 
between dCK, TK2 and gemcitabine (described in sections 1.3.2.1 Thymidine kinases, 1.4 
Project rationale, and in the abstract below), such that TK2 may contribute to levels of 
dCTP that negatively regulate dCK; both under normal conditions and when using 
gemcitabine. 
4.1. Abstract 
Mitochondrial thymidine kinase 2 (TK2) preferentially phosphorylates thymidine to 
generate thymidine monophosphate (dTMP). TK2 also phosphorylates deoxycytidine to 
generate dCMP, a precursor for dCTP -- an example of TK2 substrate promiscuity. dCTP 
negatively regulates deoxycytidine kinase (dCK), the enzyme that primarily 
phosphorylates deoxycytidine, but also phosphorylates the anticancer drug 
gemcitabine. Gemcitabine activation requires phosphorylation. Thus, there is a 
therapeutic advantage to high dCK in tumour cells treated with gemcitabine, as it 
activates the drug. Antisense knockdown of TK2 could reduce TK2-produced dCMP, thus 
decreasing dCTP levels and its inhibition of dCK.  This would subsequently lead to 
increased dCK activity, gemcitabine activation, and anticancer effectiveness. 
Importantly, gemcitabine is a very poor target for direct phosphorylation by TK2. Given 
the substrate promiscuity of TK2, we hypothesized that: (1) TK2 can mediate human 
tumour cell resistance to gemcitabine, and (2) antisense downregulation of TK2 can 
overcome that resistance. Downregulation of TK2 using siRNA sensitized MCF7 and HeLa 
cells (high and moderate TK2 expressers, respectively) to gemcitabine, but did not 
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sensitize A549 cells (low TK2 expresser). Combined treatment with TK2 siRNA and 
gemcitabine increased dCK enzyme levels. We also explored the hypothesis that TK2 
siRNA-induced drug sensitization is mediated by mitochondrial damage. Consistent with 
this hypothesis, we observed that treatment of TK2 expressing human tumour cells with 
TK2 siRNA and gemcitabine, compared to the control siRNA and gemcitabine: 1) altered 
mitochondrial redox status, 2) decreased mitochondrial DNA (mtDNA:nDNA ratio), and 
3) decreased mitochondrial activity. This is the first demonstration of a direct role for 
TK2 in gemcitabine resistance, or any independent role in cancer drug resistance, and 
further distinguishes TK2 from other dTMP-producing enzymes [cytosolic TK1 and 
thymidylate synthase (TS)]. siRNA knockdown of TK1 and/or TS in combination with TK2 
siRNA and gemcitabine did not cause further sensitization. This phenomenon is specific 
to targeting of TK2. 
4.2. TK2 expression in human tumour cells 
Immunoblot analysis indicates that MCF7, HeLa and A549 human tumour cell lines differ 
with respect to basal TK2 protein expression levels (Figure 20). They will be designated 
as TK2HIGH (MCF7), TK2MEDIUM (HeLa) and TK2LOW (A549) cells. A549 cells have 25% of the 
amount of TK2 seen in HeLa levels and 7% of the amount in MCF7.  
 
 
 
 
 
 
 
  
Figure 20: Basal TK2 expression in MCF7, HeLa and A549 cells.
Basal TK2 expression levels in MCF7(TK2
Immunoblots show representative triplicate independent samples (Ld, molecular 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIGH), HeLa(TK2MEDIUM) and A549(TK2LOW
80 
 
) cell lines. 
weight ladder). 
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4.3. TK2 siRNA knockdown 
4.3.1. TK2 siRNA decreased TK2 protein and mRNA  
MCF7 (TK2HIGH) cells were transfected with either 10 nM of control siRNA (C2 or C3) or 
10 nM of TK2-targeting siRNA (TK2#9 or TK2#11) and replated 4 h post-transfect as 
indicated in materials and methods section 2.4.1.2. Experiments lasting longer than 24 h 
post-transfection with siRNA (including time-course and drug-treatment experiments) 
and Table 4. Cell lysates and mRNA were then collected at 24, 48, 72, and 96 h post-
transfection and immunoblotting and qPCR were performed. 
In MCF7 cells, TK2-targeting siRNAs (TK2#9 and TK2#11) decreased TK2 protein by 20-
25% compared to control siRNAs (C2 and C3) at 72 and 96 h post-transfection (Figure 21 
A). Similar to MCF7 cells, TK2 protein down regulation could be seen in HeLa cells 96 h 
post-transfection with TK2 siRNAs; a 35-45% reduction in TK2 protein levels (Figure 22). 
Results for TK2 mRNA levels taken from concurrent experimental MCF7 samples show 
that TK2 mRNA was reduced by 60-75% as compared to control treated cells at 24-96 h 
post-transfection (Figure 21 B).  
TK2LOW, A549 cells line served as a control for some experiments as TK2 downregulation 
by siRNA was modest. A549 cells have 25% of the amount of TK2 seen in HeLa levels and 
7% of the amount in MCF7 (Figure 20). 
 Figure 21: TK2 protein and mRNA levels 24
cells. 
MCF7 (TK2HIGH) cells were transfected with 10 nM and replated 4 h post
methods section. Cell lysates were collected at 48, 72, and 96 h post
concurrent mRNA samples were collected at 24, 48, 72, and 96 h post
TK2 protein levels in MCF7 cells, 48
in MCF7 cells 24-96 h post-transfection with 10 nM siRNA. 
a percent of the amount in cells transfected with control
*different from cells treated with C2 or C3 siRNA (
#different from cells treated with C2 siRNA (
-96 h after TK2 siRNA transfection in MCF7 
-transfect as indicated in 
-transfection and 
-transfection. 
-96 h post-transfection with 10 nM TK2 siRNA.
For both graphs, results are shown as 
, non-targeting C2 siRNA
p < 0.05 Student’s t test and/or ANOVA). 
p < 0.05 Student’s t test and/or ANOVA).
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A) Relative 
 B) TK2 mRNA 
 on that day. 
 
  
 
Figure 22: TK2 expression in HeLa cells 96 h post
HeLa cells , 96 h post-transfection with 10 nM TK2 siRNA. In both cases, relative TK2 protein is 
shown as a percent of the amount in cells transfected with control, non
Results are shown as a percent of the amount in cells transfected with control, non
siRNA. *different from cells treated with C2 or C3 siRNA (
Immunoblots show representative triplicate independent sa
 
 
 
-transfection with 10 nM of siRNA.
-targeting C2 s
p < 0.05, Student’s t test or ANOVA).
mples (Ld, molecular weight ladder).
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4.3.2. Differences in transfection efficiency do not account for variable responses to 
TK2 siRNA. 
To help ensure that any future biological responses, or lack thereof, to TK2 antisense 
siRNA downregulation were not attributable to variability in siRNA transfection 
efficiency, experiments looking at transfection efficiency of MCF7, HeLa, and A549 cells 
were carried out. The HT-29 cell line was used as a negative control as the cell line does 
not transfect well using LF2K transfection reagent. Cells were transfected with either 10 
nM Cy3-TS siRNA, or TS siRNA #4 (which has the same sequence as Cy3-TS siRNA but 
lacks the Cy3 fluorophore on the 5’-end). Untreated cells were used as experimental 
controls. Flow cytometry for Cy3 fluorescence was performed at 4 h post-transfection; 
the timing was in keeping with experimental protocol used where cells are replated 4 h 
after transfection (Materials and Methods Section 2.4.1.2. Experiments lasting longer 
than 24 h post-transfection with siRNA (including time-course and drug-treatment 
experiments)). 
MCF7, HeLa, and A549 cells had similar siRNA transfection efficiencies (Figure 23) 
indicating that differences among the cell lines with respect to the consequences of 
transfection with TK2 siRNA are not attributable to differential transfectability. By 
comparison, under the same conditions as the MCF7, HeLa and A549 cell lines, the HT-
29 cell line showed a much lower increase in Cy3 mean fluorescence intensity (MFI) 
compared to its control when transfected with Cy3 siRNA (Figure 23). 
 
 
 
 
 Figure 23: siRNA transfection efficiencies of MCF7, HeLa, and A549 cell lines.
A) Cells were untransfected (white bars), transfected with unlabeled TS siRNA (grey bars), or 
transfected with Cy3-labeled TS siRNA (black bars). Mean 
determined by flow cytometry 4 h post
the percent increase in MFI compared to untransfected cells. *different from untransfected cells or 
cells transfected with unlabeled TS siRNA cells (
the results from A) for each cell line showing untreated cells (red), TS siRNA treated cells (blue) and 
Cy3-TS siRNA treated cells (orange). HT
control.  
fluorescence intensity (MFI) was 
-transfection with 10 nM siRNA using LF2K. Data are shown as 
p < 0.05, ANOVA). B) Representative histograms of 
-29 cell line is a hard-to-transfect cell line that was 
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used as a 
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4.4. Antisense knockdown of TK2 sensitizes TK2
MEDIUM
 (HeLa) and TK2
HIGH
 (MCF7) 
cells, but not TK2
LOW
 A549 cells, to gemcitabine 
The effect of antisense-mediated TK2 knockdown on human tumour cell proliferation 
and sensitivity to gemcitabine was assessed in response to two different control (C2 or 
C3) and two different TK2-targeting siRNAs (#9 and #11, complementary to different 
portions of the TK2 mRNA sequences, Table 3). TK2#9 siRNA (compared to C2 non-
targeting siRNA), or TK2#11 siRNA (compared to C3 non-targeting siRNA), were used to 
reduce TK2 in all 3 cell lines and the effect on sensitivity to growth inhibition by 
gemcitabine was assessed.  
TK2 siRNA sensitized TK2HIGH MCF7 cells and TK2MEDIUM HeLa cells to gemcitabine 
(multiple drug concentrations from IC20 to IC80) (Figure 24 and Figure 25). TK2 
knockdown in TK2HIGH MCF7 cells by either TK2 siRNA enhanced gemcitabine-mediated 
reduction in cell proliferation by 30-50% (Figure 24 A-B) and TK2MEDIUM HeLa cells by 15-
50% (Figure 25 A-B). TK2#11 siRNA treatment of HeLa cells sensitized only to mid-range 
concentrations of gemcitabine (4 nM and 6 nM). TK2 siRNA treatment did not sensitize 
TK2LOW (A549) cells to any tested gemcitabine concentration (Figure 26). Experiments 
were carried out concurrently for these cell lines, meaning they were exposed to the 
exact same transfection mixture.  
To isolate siRNA-induced sensitization to gemcitabine from off-target siRNA effects, 
treatment with siRNAs alone (without gemcitabine) were deemed to have 100% 
survival, in accord with our observation that there was no detectable reduction in 
proliferation induced by control siRNAs alone (C2 or C3) or TK2-targeting siRNAs alone 
(TK2#9 or TK2#11)(Figure 27). 
 Figure 24: siRNAs targeting TK2 sensitize MCF7 (TK2
gemcitabine.  
MCF7 cells were transfected with 10 nM of 
treated with gemcitabine as described in 
cell counting at 96 h post-transfection. Data is expressed 
after treatment with siRNA alone (without drug). *different from cells treated with control, non
targeting siRNA (C2 or C3) at the same gemcitabine concentration (
HIGH
) human tumour cells to 
A) C2 or TK2#9, or B) C3 or TK2#11 siRNAs and 
Materials and Methods. Proliferation was measured by 
as a percent of the number of cells 
p < 0.05, Student’s 
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-
t test). 
 Figure 25: siRNAs targeting TK2 sensitize HeLa (TK2
gemcitabine. 
HeLa cells were transfected with 10 nM of 
treated with gemcitabine as described in 
cell counting at 96 h post-transfection. Data is expressed as a percent of the number of cells 
after treatment with siRNA alone (without drug). *different from cells treated with control, non
targeting siRNA (C2 or C3) at the 
MEDIUM
) human tumour cells to 
A) C2 or TK2#9, or B) C3 or TK2#11 siRNAs and 
Materials and Methods. Proliferation was measured by 
same gemcitabine concentration (p < 0.05, Student’s 
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-
t test). 
 Figure 26: siRNAs targeting TK2 did not sensitize A549 (TK2
gemcitabine.  
A549 cells were transfected with 10 nM of 
treated with gemcitabine as described in 
cell counting at 96 h post-transfection. Data is expressed as a percent of the number of cells 
after treatment with siRNA alone (without 
 
LOW
) human tumour cells 
A) C2 or TK2#9, or B) C3 or TK2#11 siRNAs and 
Materials and Methods. Proliferation was measured by 
drug). There are no significant differences to report. 
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 Figure 27: TK2 siRNAs alone do not affect human tumour cell proliferation. 
Data for cell lines are the results of the 0 nM gemcitabine condition presented in Figure 2
A) MCF7, B) HeLa, and C) A549 c
Proliferation was measured by counting cells as described in 
Proliferation of cells treated with control, non
values for cells transfected with TK2#9 siRNA are expressed as a percent of values in cells 
transfected with C2 siRNA. Proliferation of cells treated with control, non
was normalized to 100% and values for TK2#11 siRNA ar
cells transfected with C3 siRNA. There are no significant differences to report.
 
ells were transfected with control or TK2-targeting siRNAs. 
Materials and Methods
-targeting C2 siRNA was normalized to 100% and 
-targeting C3 siRNA 
e expressed as a percent of values in 
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4.5. Combined treatment with TK2 siRNA and gemcitabine reduces TK2 
and increases dCK 
 
4.5.1. Analysis of TK2 and dCK protein levels 
Cell lysates (and mRNA) for TK2HIGH(MCF7) and TK2MEDIUM(HeLa) cells were collected 96 h 
after transfection with siRNA and treatment with gemcitabine (4 nM). Immunoblot 
analysis of cell lysates assessed TK2 and dCK enzyme levels under the same conditions. 
In both cell lines, with or without gemcitabine, TK2 protein levels are decreased by TK2 
siRNA (Figure 28 A & C).  
Combined treatment with TK2 siRNA and gemcitabine reduced TK2 protein levels (as 
seen without gemcitabine present) and increased dCK levels in both MCF7 and HeLa 
cells (Figure 28 B & D). When HeLa cells were also exposed to gemcitabine, treatment 
with TK2 siRNA #9 resulted in a 25% decrease in TK2 protein and a 60% increase in dCK 
protein compared to cells treated with C2 siRNA (Figure 28 C-D); similar results are seen 
with TK2 siRNA #11 is compared to C3 siRNA.  
In TK2HIGH(MCF7) cells, a similar increase in dCK accompanied TK2 siRNA downregulation 
of TK2 (Figure 28 A-B). When MCF7 cells were also exposed to gemcitabine, treatment 
with TK2 siRNA #9 resulted in a 30% decrease in TK2 protein and a 45% increase in dCK 
protein levels compared to C2 siRNA treated cells (Figure 28 A-B). When treated with 
TK2 siRNA #11, after exposure to gemcitabine, there was a 30% decrease in TK2 protein 
levels and a 70% increase in dCK protein levels compared to C3 siRNA (Figure 28 A-B). 
4.5.2. Analysis of TK2 and dCK mRNA levels 
At 96 h post-transfection with siRNA and treatment with gemcitabine, mRNA samples 
were collected for both MCF7 and HeLa cells. qPCR was performed to assess TK2 siRNA 
downregulation of TK2 mRNA in the presence and absence of gemcitabine (4 nM). In 
both cell lines, with or without gemcitabine, TK2 mRNA levels are decreased by TK2 
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siRNAs (Figure 29) at 96 h post-transfection. In the MCF7 cells, treatment with either 
TK2#9 or TK2#11 siRNA resulted in a 55% decrease in TK2 mRNA levels compared to 
control siRNAs (C2 or C3) (Figure 29 A). In the HeLa cell line, there was a 30-45% 
reduction in TK2 mRNA levels, as compared to control siRNAs, after treatment with TK2-
targeting siRNAs (Figure 29 B).  
 
 
 
 
 
 
 
 
 
 
 
 Figure 28: TK2 knockdown and 
HeLa cells. 
MCF7(A-B) and HeLa (C-D) cells were transfected with C2, C3, TK2#9 or TK2#11siRNAs, treated 
with gemcitabine, and relative TK2 and dCK protein levels measured 96 h post
described in Materials and Methods
representing 3 independent experiments. *different from cells transfected with control, non
targeting siRNA (p < 0.05, Student’s 
without gemcitabine (p < 0.05
Figure 29 for siRNA-mediated knockdown of TK2 mRNA in the same cells for which these data 
are shown. 
gemcitabine treatment increased dCK in MCF7 and 
-
. Bars represent means ± S.E.M for n = 8 – 
t test). #different from cells treated identical si
, Student’s t test). See  
93 
 
transfection as 
9 samples 
-
RNA but 
  
Figure 29: TK2 mRNA levels in MCF7 and HeLa cells after treatment with 
and 4 nM gemcitabine. 
MCF7 (A) and HeLa (B) cells were transfected with siRNA, treated with gemcitabine and relative 
TK2 mRNA levels measured 96 h post
and dCK protein was measured in the s
Data is expressed as a percent of non
cells transfected with C2 or C3 siRNA (
-transfection as described in Materials and Methods
ame experiment and that data is presented in 
-targeting control C2 siRNA without drug. *different from
p < 0.05, ANOVA).  
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TK2 siRNAs 
. TK2 
Figure 28. 
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4.6. Sensitization effects are specific to TK2: siRNAs targeting other 
dTMP-producing enzymes do not sensitize to gemcitabine 
 
TK2 is only one of three enzymes that mediating dTMP synthesis: thymidylate synthase 
(TS) is responsible for de novo dTMP production and TK1 is an alternative salvage 
enzyme to TK2 [174, 272]. Consequently, further experiments were performed to assess 
if sensitization to gemcitabine was specific to TK2 enzyme or to dTMP-producing 
enzymes in general. Sensitization of TK2MEDIUM(HeLa) cells to gemcitabine (0-7.5 nM) in 
the context of siRNA knockdown of TS and TK1, in addition to knockdown of TK2, was 
assessed. 
Only TK2 knockdown, and not TS or TK1 knockdown, sensitized HeLa cells to 
gemcitabine (Figure 30 A-D); of 4 tested gemcitabine concentrations, at only one (6 nM) 
did TK1 reduction sensitize to a detectable degree, which was minimal and to a lesser 
degree than reduction of TK2 (Figure 30 B). When siRNA treatments were combined to: 
i) reduce both TS and TK2, ii) reduce both TK1 and TK2, or (iii) reduce TS, TK1, and TK2 
simultaneously in a triple-targeting approach, the combinations did not increase 
sensitization to gemcitabine to a greater extent that observed by TK2 knockdown alone, 
at all tested gemcitabine concentrations (3-7.5 nM). Thus, sensitization to gemcitabine 
appears to be specific to knockdown of TK2. 
  
 
 
 Figure 30: siRNA targeting of TK2, but not TS or TK1, contributes to sensitization to 
gemcitabine. 
HeLa cells were transfected with siRNAs targeting TS, TK1 and TK2 in various combinations, 
treated with gemcitabine at either 
proliferation measured at 96 h post
indicate means ± SEM (n = 3
treated with control, non-targeting C2 siRNA without gemcitabine. *different from cells 
transfected with C2 siRNA but otherwise treated ident
 
A) 3 nM, B) 4 nM, C) 6 nM, or D) 7.5 nM and the effect on 
-transfection as described in Materials and Methods
-6 independent experiments) as a percent of proliferation of cells 
ically (p < 0.05, ANOVA).
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4.7. Treatment with TK2 siRNA and gemcitabine affects mitochondria 
4.7.1. Combined treatment with TK2 siRNA and gemcitabine decreases mitochondrial 
DNA content 
AlamarBlue (resazurin) is an indicator of redox activity and dependent on mitochondrial 
function including electron transport and oxidation during cellular respiration [273]. As 
TK2 is a mitochondrial enzyme, sensitization to impairment of mitochondrial function as 
a consequence of TK2 knockdown in the context of gemcitabine treatment was 
subsequently assessed.   
Total DNA was collected from MCF7 and A549 cells 96 h after treatment with TK2 siRNA 
and gemcitabine (treated at the IC50, as determined in cells treated with TK2 siRNAs) 
and mtDNA:nDNA ratios assessed as described in methods section 2.8. Measurement of 
mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). TK2 siRNA-induced sensitization 
to gemcitabine in TK2 expressing MCF7 cells (Figure 24) was accompanied by reduction 
in the mtDNA:nDNA ratio (Figure 31 A). There was no reduction in that ratio in 
identically-treated TK2LOW A549 cells (Figure 31 B), consistent with the lack of 
gemcitabine sensitization induced by TK2 siRNA in those cells (Figure 26).  
 
 Figure 31: TK2 siRNA and gemcitabine decrease mitochondrial DNA in TK2
cells but not in TK2
LOW
(A549) cells. 
MCF7 and A549 cells were transfected 
determined in each cell line after TK2 siRNA transfection) and the mtDNA:nDNA ratio 
determined 96 h later as described in 
of cells treated with C2 siRN
C3 control siRNAs and otherwise treated identically (
 
with siRNA, treated with gemcitabine (the IC
Materials and Methods. Data are expressed as a percent 
A without gemcitabine. *different from cells transfected with C2 or 
p < 0.05, ANOVA). 
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(MCF7) 
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4.7.2. Combined treatment with TK2 siRNA and gemcitabine decreases mitochondrial 
activity. 
Relative mtDNA content (the mtDNA:nDNA ratio) is an indirect indicator of mtDNA 
function and mitochondrial biogenesis and activity [140]. MitoTracker CMX ROS staining 
depends on intact, functioning, mitochondrial membrane and the degree of staining is 
correlated with intact mitochondrial membrane potential and mitochondrial activity. 
We assessed mitochondrial functioning more directly using a MitoTracker probe and 
flow cytometry (see material and methods section 2.9.2. Determination of mitochondrial 
activity using MitoTracker® Red CMXRos). 
TK2 knockdown in TK2HIGH(MCF7) cells decreased mitochondrial activity at both tested 
concentrations of gemcitabine (3 and 5 nM)(Figure 32 A). TK2 siRNA treatment of 
TK2MEDIUM(HeLa) cells decreased mitochondrial activity at only the highest concentration 
(7 nM) of gemcitabine (Figure 32 B). TK2 siRNA treatment of TK2LOW(A549) cell line did 
not affect mitochondrial activity in combination with gemcitabine (Figure 32 C). In TK2 
expressing cell lines, combine treatment with TK2 siRNA and gemcitabine decreases 
mitochondrial membrane potential and activity. Treatment with TK2 siRNA, as a single 
agent, did not result in changes in MitoTracker staining compared to non-targeting 
control siRNA (C2) in these cell lines (Figure 32). 
 
 
 
 
 Figure 32: TK2 siRNA and gemcitabine decrease mitochondrial activity in TK2 
expressing MCF7 and HeLa cells, but not in TK2
MCF7 (A), HeLa (B) and A549 (
gemcitabine (2 different concentrations) for 96 h, and mitochondrial activity measured as 
described in Materials and Methods
transfected with C2 siRNA and exposed to the same gemcitabine concentration. *different from 
cells transfected with C2 siRNA and treated with the same concentration of gemcitabine (
0.05, Student’s t test). 
LOW
 A549 cells. 
C) cells were transfected with siRNAs and treated with 
. Data are expressed as a percent of the mean in cells 
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Chapter 5  
« Discussion » 
Research data will be discussed with a focus on implications for the field and future 
directions. The chapter has been broken down into subheadings of major points for 
discussion. Discussion points previously published have been updated and expanded. 
5.1. Resistance to TS-targeting drugs and antisense mediated  by TK1 
or TK2 
5.1.1. TS-targeting drugs in combination with siRNAs targeting TS and TK1 or TK2 
Both thymidylate synthase and thymidine kinases mediate production of dTMP for DNA 
synthesis and repair. The activity of both pathways increases intracellular dTMP and can 
potentially contribute to tumour cell resistance to drugs targeting TS. I hypothesized 
that, when TS is inhibited by anti-TS drugs and/or TS siRNA, TKs are important in 
mediating resistance to those agents. Consequently (and in addition), I hypothesized 
that siRNA targeting TK alone or in combination with TS siRNA would further enhance 
the effectiveness of TS-targeting drugs. 
To test these hypotheses, I treated HeLa and MCF7 cells with siRNAs targeting TS alone, 
TK1 or TK2 alone, or TS siRNA in combination with siRNA targeting TK1 or TK2. To 
validate this approach, it was important to first establish that simultaneous 
administration of siRNAs targeting different mRNAs, at the siRNA concentrations 
employed in these experiments, did not affect the capacity of each siRNA to lower the 
level of its target mRNA. Previous reports (by our group and others) have suggested that 
combining different siRNAs can have reciprocal and non-reciprocal inhibitory effects on 
each other’s activity due to competition for entry into RISC complexes, and/or direct 
base-pairing with each other because of short regions of complementarity [77, 100, 
219]. Each of the siRNAs used in this study downregulated their target mRNA, alone or 
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in combination. Targeting TS mRNA had no effect on TK1 or TK2 mRNA levels and vice 
versa (Figure 3 and Figure 4). All siRNAs were more potent in reducing target mRNA 
levels in HeLa than in MCF7 cells, and TS siRNAs were generally more effective than 
siRNAs targeting TK1 or TK2 (Figure 3and Figure 4). The capacity of 2 different siRNAs to 
downregulate each mRNA target were compared, and only the most potent was used 
for subsequent experiments in HeLa cells (described in Chapter 3).  
TS siRNA increased 5FUdR-mediated inhibition of HeLa cell growth by approximately 
50% (Figure 5A) as previously reported by our group [195, 215-217, 219, 271]. When 
TK2 siRNA was combined with TS siRNA, it increased sensitivity to 5FUdR by 
approximately 25% more than treatment with TS siRNA alone (Figure 5 A-B). The 
phenomenon was enzyme-specific: TK1 siRNA combined with TS siRNA did not add to 
the increase in drug sensitivity induced by TS knockdown. These data strongly suggest 
that at least one TK enzyme (TK2) mediates sensitivity to 5FUdR. However, that 
participation appears to be indirect as siRNA-mediated knockdown of either TK2 or TK1 
alone had no effect, under these experimental conditions, on 5FUdR sensitivity (Figure 
5B). This is consistent with a model in which TS-mediated synthesis of thymidylate is the 
predominant cellular source (which is the case under normal conditions [222]), but 
where alternative TK-mediated production can partially compensate when de novo 
thymidylate synthesis is impaired by combined treatment with TS siRNA (to decrease TS 
mRNA) and 5FUdR (to decrease TS enzyme activity).  
Although our data provide evidence of a role only for TK2 with respect to 5FUdR 
sensitivity, involvement of TK1 under different conditions cannot be excluded. TK1 
activity and expression is generally higher in proliferating cells compared to TK2 [222, 
274] and the degree of TK1 knockdown achievable using this technology may not be 
sufficient to enhance the effects of combined TS siRNA and 5FUdR. We have previously 
reported that a threshold exists in antisense knockdown of TS to enhance sensitivity to 
TS-targeting drugs [215]. I suggest that a similar threshold could exist for TK1 and/or 
TK2, and that threshold may differ between the two. If so, a smaller decrease in TK2, 
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compared to TK1, might be all that is required to induce a significant effect to 5FUdR 
under our experimental conditions. The converse may be true for pemetrexed. Finally, 
although we assessed the role of both TK1 and TK2 in combination with 5FUdR 
treatment at the IC50 concentration, the effect of TK1 downregulation might be evident 
only in combination with higher 5FUdR concentrations that reduce TS activity and cell 
viability more profoundly. These possibilities are appropriate for future investigation. 
Issues such as those discussed above might be responsible for reports that targeting TK1 
alone had no effect on sensitivity to TS-targeting drugs [220, 245]. Those studies may 
also have been limited by the use of 5FU (a less specific TS inhibitor than 5FUdR [202]), 
their sole focus on TK1 (TK2 had not previously been assessed as a potential cancer 
therapeutic target), and the use of dipyridamole for global inhibition of nucleoside 
transporters rather than specific inhibition of thymidylate production. Early clinical trials 
aimed at disruption of the TK-mediated salvage pathway were likely limited by the 
available technology, method of administration, and bioavailability of dipyridamole 
[220, 221, 275]. Regardless, these early results still suggested that thymidine salvage 
was an important factor in response to TS-targeting drugs and folate inhibitors.  
TK siRNA-mediated enhancement of the increase in drug sensitivity induced by TS siRNA 
was not restricted to 5FUdR. Combined treatment with TK1 siRNA and TS siRNA 
enhanced sensitivity to pemetrexed (a multi-targeted antifolate with a different mode 
of action than 5FUdR) by approximately 30% more than the enhancement induced by TS 
siRNA alone (Figure 9 A-B). Similar to TK effects on 5FUdR sensitivity, the phenomenon 
was enzyme-specific. In this case, however, enhancement was caused by TK1 siRNA and 
not TK2 siRNA (Figure 9 A). Therefore, although our data show that TK plays a role in 
sensitivity to two different TS-targeting drugs, sensitivity to 5FUdR and pemetrexed in 
response to knockdown of each of the two TK enzymes is different, for reasons that are 
not yet clear. Although both pemetrexed and 5FUdR are TS inhibitors, their interactions 
with TS and other cellular targets are quite different. Pemetrexed, unlike 5FUdR, 
interacts with multiple folate-dependent enzymes required for production of DNA and 
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RNA intermediates, including GARFT and DHFR [276]. Differential roles for TK enzymes 
in connection with inhibition of individual or multiple folate-requiring enzymes have not 
yet been explored. In particular, TK1 is localized primarily in cytoplasm and TK2 in 
mitochondria [222], and the contribution of mitochondrial thymidine and folate 
metabolism to drug sensitivity is unknown. Our data suggest non-overlapping functions 
of TK1 and TK2, perhaps based on cellular location, that require additional investigation 
and this will be discussed further in the paragraphs that follow.   
An unexpected finding was that treatment with TS siRNA in combination with 5FUdR 
increased TK1 protein (Figure 7 C), and TS siRNA combined with pemetrexed increased 
TK2 protein (Figure 12 C). The increases were not apparently due to increased gene 
transcription since they were evident in the absence of increased TK1 or TK2 mRNA 
(Figure 7 A and Figure 12 A). Whatever the mechanism, these increases in response to 
TS inhibition support the hypothesis that TKs could mediate enhanced cell survival (and, 
conversely, knockdown of TKs may reduce that survival in tumour cells) when TS activity 
is reduced. In support of this, induction of TK1 in response to TS inhibition by 5-FU (the 
prodrug of 5-FUdR) has been reported and invoked as a mechanism for increased 
uptake of 3’-deoxy-3’-[18F]fluorothymidine (the so-called “flare response”) [245, 277]. 
That report is consistent with our observation of increased TK1 after treatment with TS 
siRNA and 5FUdR. Our observation of a specific increase in TK2 protein in response to 
pemetrexed (indeed, to any TS-targeting drug) is novel and currently under investigation 
in our laboratory.  
It is possible that the observed increases in the TK1 or TK2 protein levels are a 
compensatory mechanism to allow the cell to cope with reduced dTMP levels when the 
level of both TS and one of the two TK enzymes are reduced. It has previously been 
reported that there is cross-talk between nuclear and mitochondrial dNTP pools [278, 
279]. It is therefore possible that dTMP produced by the action of TK1 (nuclear encoded 
gene; cytosolic protein) could compensate for lack of TK2 (nuclear encoded gene; 
mitochondrial protein), and vice versa. However, the enzyme-specific increase in TK1 
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and TK2 in response to 5FUdR and pemetrexed, respectively, does not explain our 
observation that siRNA-mediated knockdown of TK2 (but not TK1) contributes to 5FUdR 
sensitivity and knockdown of TK1 (but not TK2) contributes to enhanced pemetrexed 
sensitivity. A partial explanation is suggested by the fact that TK1 is required for 
phosphorylation of 5FUdR (a prodrug) to produce the active FdUMP metabolite that 
inhibits TS [202, 280]. This dual role for TK1 – both in generating thymidylate and in 
activating 5FUdR – could explain the observation that knockdown of TK1 does not 
sensitize cells to combined TS antisense and 5FUdR treatment (i.e., TK1 reduction could 
simultaneously reduce thymidylate and sensitize to 5FUdR, but also reduce the amount 
of active 5FUdR available to act on tumour cells). Regardless of this, however, the 
different sensitization induced by combined knockdown of TS and TK1 (increased 
sensitivity to pemetrexed) compared to combined knockdown of TS and TK2 (increased 
sensitivity to 5FUdR) remains unexplained. Experiments to further explore the 
differential involvement of TK1 and TK2 in sensitivity to different classes of TS-targeting 
drugs (where those drugs are applied at concentrations other than the IC50, and where 
TK1 and TK2 are over-expressed) are appropriate future steps.  
siRNA-mediated down-regulation of TS, alone or in combination with siRNA knockdown 
of TK1 or TK2, had no effect on sensitivity to cisplatin (Figure 13). This agrees with 
previous reports that antisense against TS increased tumour cell sensitivity specifically 
to TS-targeting drugs, but not to chemotherapeutics that do not target TS [219, 271].  It 
also supports the hypothesis that modulation of TK activity affects sensitivity to anti-TS 
drugs. This is further supported by the results of Figure 30 (see Chapter 4), where 
results of experiments using TS siRNA in combination with gemcitabine are presented. 
Overall, these data support the hypothesis that TK enzymes are capable of reducing 
cellular sensitivity to TS-targeting drugs when the drugs are administered in 
combination with antisense molecules (siRNA) against TS. I demonstrate, for the first 
time, that a combinatorial RNAi approach (TS siRNA plus TK siRNA) enhanced human 
tumour cell sensitivity to two different TS-targeting drugs, and did so more effectively 
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than by reduction of TS using TS siRNA alone. In addition, these data revealed a novel 
distinction between TK1 and TK2 in their roles in sensitivity to TS-targeting drugs with 
different modes of action (TK2 and the nucleoside inhibitor 5FUdR, TK1 and the 
antifolate drug pemetrexed). TK1 and TK2 are potential therapeutic targets to enhance 
tumour sensitivity to TS-targeting drugs with there being TK enzyme-specificity for 
certain classes of drug (antimetabolite or antifolate).  
5.1.2. TS-targeting drugs in combination with siRNAs targeting TS, TK1 and TK2 
To further assess the role of the TK enzymes in mediating resistance to TS-targeting 
drugs and antisense, experiments were carried out in HeLa cells in which all 3 dTMP 
producing enzymes (TS, TK1 and TK2) were knocked down with siRNA and treated with 
either 5FUdR or pemetrexed. In the context of treatment with 5FUdR, the addition of 
TK1 siRNA to the combination of TS siRNA and TK2 siRNA did not yield further 
sensitization beyond the level induced by TS siRNA alone.  Specifically, treatment with 
the triple combination of targeting siRNA molecules did not improve HeLa cell sensitivity 
beyond that of TS siRNA (striped bars, Figure 15). A similar result was observed when 
the triple combination of siRNAs was used in combination with pemetrexed as the TS-
targeting small molecule drug. The addition of TK2 siRNA to the combination of TS siRNA 
and TK1 siRNA did not result in further sensitization to the anti-proliferative effects of 
pemetrexed beyond that induced by TS siRNA alone (hatched bars, Figure 16).  
These results were surprising, as prior data showed that the level of both TK enzymes 
increased in response to TS downregulation, suggesting that both TK1 and TK2 are 
involved in compensating for the lack of de novo production of thymidylate through the 
action of TS. Specifically: (i) TK1 protein levels increased after combined treatment with 
TS siRNA and TS plus TK2 siRNA in the context of 5FUdR (Figure 7), and (ii) TK2 protein 
levels increased after combined treatment with TK1 and TS siRNA in the context of 
pemetrexed (Figure 12). It is possible that downregulation of all 3 dTMP-producing 
enzymes by transient siRNA transfection was not sufficient to assess the effect of 
inhibition of both de novo and salvage pathway production of dTMP in the context of 
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TS-targeting drugs. However, the likelihood of this is small as antisense knockdown of 
TK2 in combination with antisense knockdown of TS and/or TK1 sensitized tumour cells 
to all tested concentrations of gemcitabine, including the triple combination siRNAs 
targeting TS, TK1, and TK2 (Figure 30). 
Published reports by others, however, suggest that these data may be consistent with 
each other. For example, Villarroya et al. [281] showed that human equilibriative 
nucleoside transporter 1 (hENT1) was more important than TK1 in maintaining dNTP 
pools when there is decreased TS and TK2 function. In their experiments with quiescent 
TK2-deficient fibroblast cells with an undepleted mtDNA phenotype, TK1 mRNA levels 
were increased without a concomitant increase in TK1 activity (in itself a somewhat 
surprising result, as dNTP pools were unchanged compared to control cells). The TK2- 
quiescent fibroblast cells were used as a model system to investigate TK enzyme 
function as de novo synthesis of dTMP should be minimal in non-cycling cells.  They 
showed that, as expected for quiescent non-cycling cells, TS mRNA was decreased 
compared to TK2- fibroblasts cells that were actively cycling  . While measurement of TS 
enzyme and/or activity (rather than simply reporting TS mRNA levels) would have been 
more informative about the potential for TS-mediated de novo production of 
thymidylate to compensate for the lack of TK2 in these cells, Villarroya's data show that 
TK1 activity was not the essential factor responsible for the observed lack of mtDNA 
depletion phenotype.  Instead, hENT1 appeared to be more important, because mtDNA 
depletion was induced in these cells when hENT1 was downregulated. Essentially, in 
quiescent TK2-deficient fibroblasts with decreased levels of TK2 protein and TS (due to 
quiescence), hENT1 is more important for maintenance of dNTP pools than TK1. 
I observed that when both TS and TK2 are targeted with siRNA during treatment with 
5UdR there is an increase in TK1 protein levels, but not mRNA (Figure 7).  However, TK1 
activity, in addition to TK1 protein and mRNA levels, was not measured. If the 
combination of TS siRNA and TK2 siRNA with 5FUdR results in cytostatic, as opposed to 
cytotoxic effects, then the situation observed by Villaroya et al. would suggest that 
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concomitant targeting of TK1 with siRNA might have no further effect on the 
sensitization of the HeLa cells to 5FUdR. If, in this situation, the state of the HeLa cells is 
similar to that of the quiescent TK2-deficient fibroblasts, and TK1 mRNA and protein 
levels do not reflect fluctuations in TK1 activity, then TK1 would not be expected to 
compensate for reductions in of TK2 and TS in order to maintain HeLa cell survival. 
Future investigation into the combined treatment of TS-targeting drugs and TS  siRNA 
and TK2 siRNA should address: (i) TK1 activity in the HeLa cells, (ii) the underlying 
mechanism for decreased HeLa (or other cell line) cell number (i.e., cell death or cellular 
arrest), and (iii) the contribution of hENT1, as this protein is present on both 
mitochondrial and cell membranes to import nucleosides into cellular compartments 
(cytosol or mitochondria) and has been implicated in compensating for decreased 
nucleotide and nucleoside levels in reports by Villarroya et al. and others [260, 281, 
282]. 
hENT1 is one of the transporters responsible for the import of thymidine, and other 
nucleosides, into cells (there are multiple hENTs as well as concentrative nucleoside 
transporters) [283]. Indeed, all nucleoside transporters have been implicated in having 
an effect on the efficacy of anticancer and antiviral nuceloside drugs [284]. Preliminary 
experiments to assess the effect of increased extracellular thymidine on combined 
siRNA and drug treatment were conducted (Figure 33). Increased extracellular 
thymidine was expected to be imported into cells and mitochondria by nucleoside 
transporters, including hENT1. Results revealed that treatment of HeLa cells with 
thymidine (10 μM) could protect against the inhibition of proliferation induced by 
5FUdR (administered at the IC50 in these cells) and by the inhibition of proliferation 
induced by administration of combined TS siRNA and 5FUdR. When TK2 siRNA and TS 
siRNA were used under the same conditions, there was still rescue of the cells by added 
thymidine, but not to the same degree as in cells treated with only with TS siRNA and 
5FUdR.  Specifically, in the context of 5FUdR treatment, TS siRNA-treated cells were 
rescued so that proliferation in the presence of 5FUdR was increased to 90% of control 
cells untreated with 5FUdR, while TS siRNA- and TK2 siRNA-treated cells were rescued 
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to 80% of control (Figure 33). The triple combination of all three siRNAs (targeting TS, 
TK1, and TK2) did not reduce the capacity of added thymidine to protect cells from 
5FUdR toxicity beyond the reduction in protection from 5FUdR toxicity mediated by TK2 
siRNA in combination with TS siRNA (Figure 33). Further experimentation was not 
pursued. This data strongly suggest that TK1 and TK2 enzymes have independent, non-
overlapping functions in normal cellular metabolism, and with respect to resistance to 
different classes of TS-targeting small molecule drugs. Those differences have not been 
previously hypothesized or reported to our knowledge. 
 
 
 
 
 Figure 33: siRNA targeting of dTMP enzymes in combination with 5FUdR 
supplemented with 10 uM thymidine. 
Experimental design and analysis
cells were treated with TS siRNA [3 nM], TK1 siRNA [3 nM] and TK2 siRNA [4 nM], or various 
combination thereof using C2 siRNA to 
concentration of siRNA whe
present, HeLa cells were grown in medium containing thymidine for a minimum of 72 h prior to 
transfection and throughout the duration of the experiment. Results are expressed a
percentage of the C2 siRNA with medium condition fold change. Bars represent mean ± S.D. for 
n = 6 samples from 2 independent experiments. *different from 
with non-targeting control (
TS siRNA alone (p≤0.05). 
 
 
 was the same as described in the legend to Figure 
bring each siRNA treatement to a 10 nM total 
rever required. For those conditions in which 10 μM
cells treated identically, but 
C2) siRNA (p≤0.05). adifferent from cells treated identically, but with 
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5.2. The effect of siRNA concentration on the magnitude of biological 
response: the pitfalls of a combinatorial RNAi approach? 
An unexpected finding while investigating siRNA-mediated reduction in cellular TS, TK1 
and TK2 was that the magnitude of biological response with respect to siRNAs in 
combination with 5FUdR or pemetrexed could be increased or decreased depending 
upon the total concentration of siRNA used. The results of Figure 15, Figure 16, and 
Figure 19 A (where the total siRNA concentration was 10 nM) as compared to Figure 17, 
Figure 18 and Figure 19 B (where the total siRNA concentration was 15 nM) showed 
that transfection of higher amounts of the targeting siRNAs (TS and/or TK1 and/or TK2) 
dampened or negated sensitization to TS-targeting drugs observed after transfection of 
lesser amounts of siRNA. Differences in response seem to be dependent upon the total 
amount of siRNA administered and were not specific to the siRNA target. 
The use of a 15 nM total siRNA concentration, in general, resulted in a lesser response 
to combined treatment with 5FUdR or pemetrexed than compared to the 10 nM total 
siRNA concentration. In fact, less total targeting siRNA combined with 5FUdR or 
pemetrexed appeared to mediate a larger decrease in HeLa and Meso H28 cellular 
proliferation than higher total concentrations of the same combination of siRNAs (TS 
and/or TK1 and/or TK2). Specifically, when HeLa cells were treated with 5FUdR or 
pemetrexed at the IC50 of those drugs, and 10 nM total siRNA concentration was used, 
there was a 50-60% increase in capacity of 5FUdR to inhibit proliferation compared to 
no sensitization induced by targeting siRNAs when a 15 nM total siRNA concentration 
was used. A similar result was obtained after treatment of Meso H28 cells (Figure 19), 
which showed a 30-45% reduction in proliferation in response to treatment with the TS 
siRNA and combinations of TS and TK siRNAs alone (no drug) at a concentration of 10 
nM, and a 0-15% reduction in proliferation when 15 nM of siRNA was used.  
Prior to carrying out the above experiments with variable total concentrations of 
combined siRNAs, it was known that when two or more siRNA (or other antisense) 
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molecules are simultaneously introduced into a system, the capacity of one or both of 
the siRNA to silence genes can be compromised [100, 112, 219, 285, 286]. Based on 
sequence, the siRNAs chosen for our studies do not bind to each, ruling out this trivial 
mechanism as a means of preventing target downregulation. I showed, that at a 10 nM 
concentration, when two targeting siRNAs were combined, the ability of the TS siRNAs, 
TK1 siRNAs and TK2 siRNAs to downregulate target mRNA and protein was the same as 
when used as a single agent (results presented in Chapter 3, for example Figure 3, 
Figure 6, Figure 11,and Figure 12). Also, in the case of TK2 siRNA and gemcitabine, the 
triple combination of siRNA did not prevent TK2 siRNA from sensitizing human tumour 
cells to gemcitabine toxicity (Figure 30).  
In general, competition between RNAi molecules can become apparent when using 
either a high concentration of antisense molecules and/or multiple antisense molecules 
within the same cell. It was surprising that the 5 nM difference between the 10 nM and 
15 nM concentrations resulted in such a profound abrogation of sensitization. This was 
particularly true because: (1) previous studies published by our lab [219] used siRNAs in 
combination with each other at concentrations as high as 50 nM and still showed a 
biological phenomenon, and (2) the results from Figure 38 in Appendix 1 indicated that 
using a targeting siRNA at lower concentrations (5 nM - 0.01 nM) and adding control, 
non-targeting siRNA to maintain constant concentrations between and among 
experiments did not impede mRNA silencing.   
Specifically, and taking TS siRNA transfection followed by 5FUdR treatment in HeLa cells 
as an example, there was a 75% vs 55% decrease in proliferation induced by 5FUdR 
when cells were transfected beforehand with a total concentration of 10 nM siRNA vs 
15 nM concentration of siRNA, respectively (Figure 15 vs. Figure 17). Furthermore, in 
the human mesothelioma-derived Meso H28 cells, there was a 90% vs 45% decrease in 
proliferation induced by 5FUdR when cells were transfected beforehand with a total 
concentration of 10 nM siRNA vs 15 nM concentration of siRNA, respectively (Figure 19 
A vs. B) when compared to drug untreated cells. These data suggest a more widespread, 
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and not target-specific, effect on cells that cannot be attributed solely to the presence 
of multiple different targeting siRNAs applied simultaneously to cells. Further to this 
point, these results are seen in the above figures both when TS siRNA is the only 
targeting siRNA present and when targeting siRNAs are used in combination.  
I hypothesize that these results are off-target effects caused by non-sequence-specific 
events related to competition for RISC. Differences in the magnitude of biological 
response produced by the siRNA concentrations indicate that these results are likely due 
to competition between the siRNA(s), and endogenous miRNAs, for entry into RISC 
complexes. I speculate that this is the case because it is the increased siRNA 
concentration that produces the lesser biological response. As these experiments use 
siRNA as the antisense molecule of choice, we can assume that competition between 
our siRNAs and endogenous miRNAs, if this is the case, is at the level of RISC complex 
proteins (Ago-2, TRBP, Dicer) and not for upstream components of the miRNA pathway 
like Dicer (for pre-processing) or Exportin-5 (for export from of miRNAs from the 
nucleus,) as the siRNAs do not require the same upstream processing by these 
components that shRNAs and miRNAs do [15, 100, 101, 103, 104, 287-289].  
With respect to dose in our initial experiments, the use of a 10 nM total siRNA 
concentration was investigated as a strategy to reduce siRNA treatments to the lowest 
concentrations possible, while maintaining maximum capacity to reduce mRNA target 
levels.  Previously, the lowest total concentration of siRNA used by our group was 25 nM 
[219]. Jackson et al. [26] reported dose response effects associated with transfection of 
MAPK14 siRNA at 5 different doses from 0.16 nM - 100 nM into HeLa cells. They showed 
that the relative magnitude of sequence non-specific off-target effects did not decrease 
with decreasing siRNA concentration. Data presented in this thesis shows that on-target 
effects can also be perturbed by overall siRNA dosage and greater on-target 
effectiveness was achieved at a lower siRNA dose compared to a higher siRNA dose. 
These data could also be interpreted to show that the relative magnitude of off-target 
effects does decrease with decreasing siRNA concentration (i.e., when using 10 nM 
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siRNA vs. 15 nM siRNA and as measured by the decrease in biological phenomenon - the 
sensitization to drugs). 
Khan et al. [286]and others [290] have shown that when even one exogenous antisense 
molecule is transfected into a cell system, there are global changes in the microRNA 
network within those transfected cells that lead to the upregulation of genes known to 
be targeted by miRNAs. Of particular interest, Khan’s computational analysis models, 
with a focus on HeLa cell transfections, determined that there was upregulation of a 
number of specific oncogenes as a result of transfection with exogenous siRNAs. In 
addition, HeLa cells were particularly sensitive to perturbations in their microRNA 
regulatory pathways. Because exogenous, transfected siRNAs and endogenous miRNAs 
compete for a limited pool of RISC proteins, factors such as siRNA potency (including the 
relative differences between exogenous siRNAs and between exogenous siRNAs and 
endogenous miRNAs) and RISC preferences for antisense strand selection may be 
exacerbated in experiments which include the introduction of multiple, exogenous, 
targeting siRNAs. It is not currently known if cells can respond to an increased load of 
siRNAs (i.e., an increased demand for RISC) by upregulation of RISC proteins to deal with 
the augmented demand and if this would restore normal patterns of miRNA regulation 
of gene expression within the cell. This information could be revealing.  If this was the 
case, it could indicate that early toxicities and/or off-target effects associated with the 
initial competition for RISC would eventually lessen with time.  
Antisense molecules are being actively pursued as therapeutics [35, 68, 71, 291-293]. 
Consequently, when using RISC-mediated antisense technology where target 
downregulation is carried out by RISC cleavage, studies to observe the overall effect on 
miRNA pathways will be important for understanding and predicting on-target effects 
(associated with a specific sequence) and off-target effects (which may also be 
sequence-specific and the result of sequence similarity among RNAs, or associated with 
pertubations in endogenous miRNAs not related to sequence) [294]. Depending on the 
objective of the study, measurement of differences in RISC-associated RNAi molecules 
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(by qPCR) before and after treatment with RNAi substrates from an exogenous source 
may be a method to optimize dosage or concentration, such that a balance is achieved 
between exogenous antisense (and on-target effects) and endogenous miRNAs (to 
reduce non-specific off-target effects) [295]. For example, to assess the extent to which 
exogenous siRNAs compete with endogenous miRNAs for RISC association, one might 
transfect in tagged siRNAs (for example, biotin), isolate RISC (or more specifically Ago-2) 
associated with tagged siRNAs by column immunoprecipitation (in keeping with the 
above example,  streptavidin) from RISC associated with endogenous miRNA substrates, 
and quantify the amount of siRNAs and miRNAs associated with the complex (again, by 
qPCR) [295-299]. It would be important to use a panel of multiple targeting siRNAs and 
control non-targeting siRNAs as it is possible that the residency time in RISC is different 
for these two types, and may also be sequence-dependent. A difference in the amount 
and type (sequence) of miRNAs associated with RISC would be taken as evidence that 
transfection of exogenous siRNAs perturbs the regulatory control of gene expression 
carried out by endogenous miRNAs. Transfecting non-targeting siRNAs in addition to 
targeting siRNAs will help distinguish between that possibility, and the possibility that 
changes in miRNA metabolism occur because of the knockdown of target mRNAs by 
siRNA and not competition for RISC. One might also use antisense oligonucleotides 
(ASOs) targeting the same mRNAs targeted with siRNA to determine whether that 
perturbs miRNA association with RISC in a fashion similar to pertubations induced by 
siRNAs.  This will help distinguish between the two possibilities, as ASOs exert their 
antisense activity via an RNase H-dependent, RISC-independent pathway.  
5.3. siRNA Knockdown of TK Sensitizes Cancer Cells to Gemcitabine 
5.3.1. The relationship between TK2, dCK and gemcitabine 
TK2 siRNA knockdown induced a relatively modest reduction in TK2 protein. Regardless, 
the capacity of that reduction to enhance the antiproliferative effect of gemcitabine was 
relatively large (up to 50%) in certain TK2-expressing cell lines (MCF7, Figure 24; HeLa, 
Figure 25).  
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A relationship among dCK, gemcitabine and TK2 that incorporates cellular responses to 
antisense knockdown of TK2 is proposed (Figure 34).  Importantly, gemcitabine is poorly 
phosphorylated by TK2. dCK is required to activate gemcitabine and increased dCK levels 
mediate gemcitabine anti-tumour action. In fact, decreased dCK levels in vitro mediate 
gemcitabine resistance [172, 300, 301]. In cells that express TK2 to a certain degree, 
reliance upon TK2 to contribute to the production of dCMP/dCTP may be greater than in 
cells with lower TK2 levels (for example, MCF7 and HeLa cells compared to A549 cells). 
When these cells are targeted with both TK2 siRNA and gemcitabine, dCK levels 
increase, potentially to compensate for decreased dCTP. However, the increased dCK 
serves only to further activate gemcitabine. Examination of the interplay between TK2, 
dCK and gemcitabine shows, for the first time, increased dCK levels in human tumour 
cells in response to combined targeting with TK2 siRNA and gemcitabine treatment 
(Figure 28). Importantly, the increase did not occur in response to either TK2 siRNA or 
gemcitabine used as single agents. 
 
  
Figure 34: Proposed relationship between TK2, dCK 
dCK phosphorylates both deoxycytidine and the anticancer drug gemcitabine. dCK is negatively 
regulated by the feedback inhibition of dCTP. TK2 phosphorylates both deoxythymidine and 
deoxycytidine. Thus, TK2 contributes to levels of dCTP th
dCK, by TK2-produced dCTP, decreases the amount of gemcitabine that can be activated by dCK 
when used as an anticancer agent. siRNA
gemcitabine, results in increased d
antiproliferative effects of gemcitabine. Thus, TK2 contributes to gemcitabine resistance.
 
 
and gemcitabine. 
at negatively regulate dCK. Inhibition of 
-mediated reduction in TK2, in combination with 
CK enzyme levels and a greater response to the 
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5.3.2. Effects on mitochondria after combined treatment with TK2 siRNA and 
gemcitabine 
The implications of decreased TK2 in the context of combined treatment with 
gemcitabine were also explored with a focus on mitochondrial toxicity. Combined TK2 
siRNA and gemcitabine appears to reduce mtDNA in preference to nDNA (Figure 31). 
The concurrent decrease in mtDNA:nDNA ratio and sensitization to gemcitabine induced 
by TK2 siRNA in TK2HIGH (MCF7) cells, but not A549 cells with low TK2, implies that TK2 is 
critically involved in tumour cell mitochondrial dysfunction and cellular toxicity in 
response to combined treatment with TK2 siRNA and gemcitabine in these cells.  
The decrease in mtDNA:nDNA ratio in the TK2HIGH (MCF7) cell line implicated increased 
mitochondrial toxicity as a potential mediator of the sensitization phenomenon seen 
when gemcitabine was combined with TK2 siRNA. Flow cytomtetry using MitoTracker 
CMX Ros confirmed a decrease in mitochondrial activity in TK2-expressing MCF7 and 
HeLa cells, but not in TK2LOW A549 cells (Figure 32). This is in keeping with the fact that 
mtDNA encodes genes specific to electron transport chain (ETC) enzymes, and that the 
magnitude of mtDNA and Mitotracker reduction in gemcitabine and in TK2 siRNA-
treated cells are not disproportionate with respect to each other. 
Fowler et al. reported that gemcitabine can inhibit the activity of human mitochondrial 
DNA polymerase γ [302]. This, in combination with a reduction in TK2, could contribute 
to a preferential decrease in mtDNA. The profile of gemcitabine toxicity has been shown 
to be similar to that of some anti-viral agents, and induces events similar to the 
pathologies seen in a heterogeneous group of disorders known as mtDNA depletion 
disorders. Interestingly, mutations and deletions in the TK2 gene have been found to 
cause mtDNA depletion disorders [251, 252, 303, 304]. We have shown that combined 
treatment with TK2 siRNA and gemcitabine results in decreased mtDNA and 
mitochondrial membrane potential and activity. These data implicate increased 
mitochondrial toxicity as a critical event in gemcitabine sensitization. Whether 
mitochondrial toxicity is the result of sensitization, or contributes to sensitization, 
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remains to be determined. However, preliminary experiments using MCF7 cells and a 72 
h end-point did not show similar mitochondrial effects, as measured by mtDNA;nDNA 
ratio and MitoTracker (data not shown), suggesting that mitochondrial toxicity is likely a  
consequence of treatment that could contribute to decreased cellular proliferation or 
increased cell death in treated cells, but only during later time points.  
There is an alternative explanation to these results based upon relative mtDNA content 
between the MCF and A549 cell lines. When we compare the relative mtDNA:nDNA 
(Figure 35) of untreated A549 cells and MCF7 cells, we see that MCF7 cells have a 
mtDNA:nDNA ratio that is approximately 85% lower than that of A549 cells. As such, it is 
possible that the MCF7 cells are inherently primed to experience increased toxicity in 
response to treatments that affect mtDNA and mitochondrial functioning. Thus, this 
effect would not be specific to TK2 targeting, although it would be specific to 
mitochondrial targeting, and gemcitabine could be combined with any other treatment 
which negatively affects mitochondrial functioning to improve upon anticancer therapy.  
These include, for example, rotenone (an ETC inhibitor) or atractyloaside (an inhibitor of 
the ADP/ATP exchanger) or other mitochondrially-targeted anticancer drugs (mitocans) 
already approved for use or under investigation [305]. Given the implied role of the 
mitochondria in contributing to tumour cell dysfunction and ROS generation (discussed 
in the Introduction, section 1.2.3.1 Relevance of mitochondria and mitochondrial DNA 
(mtDNA) in cancer) it is no surprise that targeting mitochondria as an anticancer therapy 
or to improve upon current anticancer therapies is currently being explored. Mitocans, 
as mentioned above, are defined as [anti-cancer] drugs whose action is achieved by way 
of mitochondrial destabilization [306, 307]. In fact, Neuzil et al. [306] reviewed a 
number of drugs that act as mitocans and classified them into 8 separate classes 
depending upon the mechanism by which they affect the mitochondria. One of these 
classes includes “drugs targeting mtDNA”, which can occur via inhibition of DNA 
polymerase y and would imply that gemcitabine itself should be considered to have 
mitocan-like effects secondary to its action upon nDNA [302].  
  
Figure 35: mtDNA:nDNA ratio in untreated A549 and MCF7 cells.
mtDNA and nDNA in MCF7 and A549 cells were measured as described 
Data are expressed as a percent of A549 cell’s mtDNA:nDNA ratio. *different from A549 ce
< 0.05, Student’s t test). 
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Others have previously suggested that TK2 plays a role in the effectiveness of 
deoxycytidine nucleoside analogues such as gemcitabine, and that the mitochondria 
could play a role in both toxicity and antitumour activity [171, 308-310]. Prior to this 
study, there has been no report of the consequences of antisense-mediated TK2 
reduction on gemcitabine effectiveness and mitochondrial function.  Indeed, the work 
described here is the first report of a tangible connection between theory and 
observation. These data identify TK2 as a potentially valuable target for anticancer 
therapy in combination with gemcitabine. Although siRNAs are difficult to administer 
effectively in vivo due to stability and pharmacokinetic challenges [30, 53, 311], 
experimental TK2-inhibiting small molecules including those reported by others [312, 
313] may be appropriate candidate TK2-targeting agents for use in combination with 
gemcitabine. Targeting of TK2 is likely to be of therapeutic value, but only in 
combination with gemcitabine or related cytidine-nucleoside-analouge drugs as siRNA-
mediated knockdown of TK2 alone did not reduce tumour cell proliferation, nor (in 
previous studies published by us) did TK2 knockdown in combination with pemetrexed, 
cisplatin, or 5FUdR reduce proliferation or sensitize to chemotherapy [264]. 
5.4 Summary  
Downregulation of TK with siRNA enhanced the capacity of TS siRNA to sensitize tumour 
cells to traditional TS protein-targeting drugs (5FUdR and pemetrexed). Combined 
antisense targeting of TS and TK1/TK2 was more effective than either siRNA used alone 
to sensitize tumour cells to the effects of TS-targeting chemotherapeutic drugs. 
Upregulation of TK1 in response to combined 5FUdR and TS siRNA, and TK2 in response 
to pemetrexed and TS siRNA, suggests new and diverging properties of TK1 and TK2. 
Enhanced sensitization to 5FUdR and pemetrexed by targeting both TS and TK with 
siRNAs suggests that the TK salvage pathways are potential targets for anticancer 
therapies when combined with molecules targeting TS mRNA and TS protein. 
Downregulation of TK2 using siRNA sensitized cancer cells to gemcitabine by as much as 
50% compared to cells treated with control siRNA. Combined treatment with TK2 siRNA 
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and gemcitabine also resulted in increased dCK enzyme levels. It was observed that 
treatment of TK2-expressing human tumour cells with TK2 siRNA and gemcitabine, 
compared to the control siRNA and gemcitabine: (i) decreased mitochondrial redox 
status (as indicated by alamarBlue), (ii) decreased mitochondrial DNA (as measured by 
mtDNA:nDNA ratio), and (iii) decreased mitochondrial activity (as measured by flow 
cytometry with MitoTracker CMX ROS). This is the first demonstration of a direct role for 
TK2 in gemcitabine resistance, or any independent role in cancer drug resistance, and 
further distinguishes TK2 from other dTMP-producing enzymes [cytosolic TK1 and 
thymidylate synthase (TS)]. siRNA knockdown of TK1 and/or TS in combination with TK2 
siRNA and gemcitabine did not cause further sensitization. This phenomenon is specific 
to targeting of TK2. 
Overall, the TKs are implicated in reducing the effectiveness of TS-targeting drugs and 
may be useful targets for cancer therapy when combined with TS-targeting antisense 
molecules, drugs targeting TS protein or, specifically in the case context of TK2,  
gemcitabine. 
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Appendix 1 
The information in this appendix pertains to initial studies done to determine 
experimental conditions, including the amount of LF2K used to transfect, siRNA 
concentrations, and whether topping up with control siRNA (so as to keep siRNA 
concentrations constant between single agent and combined treatments) would effect 
the capacity of the -targeting siRNA to downregulate its target mRNA. The assumption 
was made that, as administered siRNA concentrations increased, the potential for 
undesirable non-specific toxicity and/or off-target effects (related to the siRNA 
sequence or to competition with miRNAs for RISC) would increase as the concentration 
of administered siRNA increased. Therefore, I assessed the capacity for targeting siRNA 
using substantially lower concentrations (picomolar) than those used in most in vitro cell 
culture studies (nanomolar) to effectively reduce target mRNA levels. In addition, 
reduction in the amount of liposomal transfection reagents to similarly reduce toxicity 
and/or off-target effects was also assessed. 
A1.1 Determining the Amount of Lipofectamine 2000 (LF2K) to Use for 
Transfections 
siRNA transfection reagents can, themselves induce off-target effects (non-specific 
mRNA downregulation) [60]. I sought to determine if it would be possible to decrease 
the total amount of LF2K used per flask without decreasing desired on-target effects 
(siRNA downregulation of target mRNA).  
HeLa cells were transfected with either C2 siRNA (5 nM) or TS siRNA #4 (5 nM) using 
different amounts of LF2K per flask (similar to what is described in Materials and 
Methods, section 2.4.1.1). The different amounts used relate to: (i) the minimum 
recommended amount for a T25 flask (10 µL) as suggested by the manufacturer, (ii) half 
of the minimum recommended amount (5 µL), (iii) a quarter of the recommended 
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amount (2.5 µL), and (iv) one tenth the minimum recommended amount (1 µL). Cells 
were collected for mRNA analysis by qPCR 24 h post-transfection. 
The results were used to identify half of the minimum recommended amount (5 uL per 
flask) as the amount of LF2K to use for our transfections. This amount was chosen as it 
allowed for TS mRNA downregulation to the same extent as the manufacturer’s 
recommended amount, but decreased off-target toxicity associated with using LF2K 
(Figure 36). At lower amounts of LF2K used (2.5 uL and 1 uL) the off-target effects of 
LF2K were further decreased, but on-target TS mRNA downregulation suffered. 
 
 
 
 
 
 
 Figure 36 Appendix: siRNA transfection of HeLa cells using different amounts of LF2K 
transfection reagent.  
HeLa cells were transfected with 5 nM total siRNA using varying amounts of LF2K 
transfection reagent. qPCR was used to examine off
associated with use of a specific amount of LF2K and to compare on
downregulation as well. Data are expressed as a percentage of the LF2K (5 uL) condition. 
Bars represent means ± S.E.M. for n = 6 samples from 2 independent experiments. * 
different from LF2K (5uL) condition identically treated cells (p < 0.05). 
 
-target TS mRNA downregulation 
-target TS mRNA 
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A1.2 Determining the Parameters of siRNA Concentrations Used for 
Experiments 
Prior to the experiments presented in this thesis, the lowest concentration of siRNA 
used for experimentation in this laboratory was 25 nM for siRNAs used as single agents 
and 50 nM for combinations of 2 siRNAs [219]. Others in the field had published work 
using lower siRNA concentrations (0.1 nM - 20 nM) and so I knew that using a lower 
concentration of siRNA was a realistic possibility [112, 314]. In order to plan 
experiments where multiple siRNAs could be administered simultaneously without 
increasing total siRNA concentrations to levels with potential for undesired toxicity 
and/or off-target effects, minimization of administered siRNA concentrations was 
desirable. In addition, I wished to control for the overall amount of siRNA that cells were 
exposed to during experiments, such that all conditions were equal: consequently I 
assessed the effect of addition of control non-targeting siRNA (C2 siRNA) to targeting 
siRNAs to bring total siRNA concentrations to 10 nM to the capacity of targeting siRNA 
to decrease target mRNA. 
HeLa cells were transfected with TS siRNA #3 at concentrations ranging from (0.01 - 10 
nM) with or without C2 siRNA top-up to 10 nM total siRNA. Cells were collected for 
mRNA analysis by qPCR 24 h post-transfection. Results show that TS mRNA was 
downregulated by TS siRNA #3 at all concentrations tested both without C2 siRNA top-
up (Figure 37Error! Reference source not found.Error! Reference source not found.) 
and with top-up (Figure 38); though siRNA concentration dependent effects on mRNA 
downregulation become apparent at concentrations less than 0.5 nM. Throughout the 
results presented in this thesis, siRNA concentrations of 10, 5, 4, and 3 nM siRNA were 
consistently used. Results here show: (i) that there should be no difference in the 
different siRNA-concentration’s ability to downregulate target mRNA levels, and (ii) that 
topping up to a 10 nM total siRNA concentration, using non-targeting control siRNA 
(C2), does not interfere with the targeting siRNA’s ability to downregulate target mRNA 
(Figure 37 and Figure 38). 
  
 
 
 
Figure 37 Appendix: TS siRNA knockdown of TS mRNA using siRNA at concentrations 
ranging from 0.01 to 10 nM. 
HeLa cells were transfected with either C2 siRNA [10 nM], C3 siRNA [10 nM] or TS siRNA 
# 3 [0.01 - 10 nM] and TS mRNA downregulation was assessed at 24 h post
by qPCR. Data are shown as a percentage of the C2 siRNA condition and bars represent
means ± S.E.M. for n = 6 samples from 2 independent experiments. * different from 
cells transfected with non
#different from cells transfected with 0.5
adifferent from cells transfected with 0.1 and 0.05 nM TS siRNA #3 (p < 0.05 by ANOVA).
 
 
 
 
 
 
-targeting control siRNA (C2 or C3) (p < 0.05 by ANOVA). 
-10 nM TS siRNA #3 (p < 0.05 by ANOVA). 
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Figure 38 Apendix: TS siRNA knockdown of TS mRNA using TS siRNA at concentrations 
ranging from 0.01 to 10 nM and topping up with C2 siRNA to 
concentration.  
HeLa cells were transfected with either C2 siRNA [10 nM], C3 siRNA [10 nM] or a range 
of TS siRNA # 3 concentrations[0.01 
10nM siRNA. TS mRNA downregulation was assessed at 2
Data are shown as a percentage of the C2 siRNA condition and bars represent means ± 
S.E.M. for n = 3 independent experiments. * different from cells transfected with non
targeting control siRNA (C2 or C3) (p < 0.05 by ANOVA).
transfected with 0.1-10 nM TS siRNA #3 (p < 0.05 by ANOVA). 
transfected with 0.05 nM TS siRNA #3 (p < 0.05 by ANOVA).
 
 
 
 
 
 
 
 
 
 
a 10 nM total 
- 10 nM] using C2 siRNA to top up each condition to 
4 h post-transfection by qPCR. 
 # different from cells 
a different from cells 
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